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 The blood-brain barrier (BBB) limits entry of most molecules into the brain and 
complicates the development of brain-targeting compounds, necessitating novel BBB 
models. This dissertation describes the first microfluidic BBB model allowing the study 
of BBB properties in relation to various chemical compounds by enabling tunable wall 
shear stress (WSS) via dynamic fluid flow, cell-cell interaction through a thin co-culture 
membrane, time-dependent delivery of test compounds, and integration of sensors into 
the system, resulting in significant reduction of reagents and cells required and shorter 
cell seeding time. Use of parallel channels first enabled simultaneous monitoring of 
multiple cell populations under a wide range (~x15) of WSS. 
 The microfluidic model formed the BBB by incorporating brain endothelial 
(b.End3) and glial (C6/C8D1A) cells at the intersection of two crossing microchannels, 
respectively representing luminal and abluminal sides, fabricated in a transparent 
polydimethylsiloxane (PDMS) substrate utilizing high-precision soft lithography 
techniques. The utilized cells were adopted from immortalized cells for high consistency 
over repeated passages and pure and proliferative culture.  
The developed microfluidic BBB model was validated by (1) expression of tight 
junction protein ZO-1 and glial protein GFAP by fluorescence imaging, and P-gp activity 
by Calcein AM, confirming key BBB proteins; (2) high trans-endothelial electrical 
  
resistance (TEER) of co-cultures exceeding 250Ωcm2 confirming sufficiently contiguous 
cell layer formation; (3) chemically-induced barrier modulation, with transient TEER loss 
by 150µM histamine (~50% for 8-15min), and increase in permeability at elevated pH 
(10.0); (4) size-dependent (668-70,000Da) compound permeability mimicking in vivo 
trends; and (5) highly linear correlation (R2>0.85) of clearance rates of seven selected 
neural drugs with in vivo brain/plasma ratios. We demonstrated the effects of WSS (0-
86dyn/cm2) on bEnd.3 properties under increasing WSS, including increase in (6) TEER, 
(7) cell re-alignment toward flow direction, and (8) protein expression of ZO-1/P-gp, and 
(9) decrease in tracer permeability. 
The developed in vitro microfluidic BBB model provides distinct advantages for 
monitoring and modulating barrier functions and prediction of compound permeability. 
Thus, it would provide an innovative platform to study mechanisms and pathology of 
barrier function as well as to assess novel pharmaceuticals early in development for their 
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This dissertation aims to address the feasibility of modeling the blood-brain 
barrier (BBB) by developing an innovative chip-based microfluidic platform. This 
chapter describes the significance of such a system, and overviews the project and 
approach taken in this dissertation to develop and characterize the described platforms. 
 
1.1 Motivation and Significance 
There is currently a prevalent and increasing burden on the healthcare industry 
over the growing number of patients suffering from neurodegenerative disorders of the 
central nervous system (CNS), notably Alzheimer’s Disease (AD), which is diagnosed in 
an estimated 24 million patients worldwide, and is projected to double every 20 years [1]. 
However, CNS drug development progress is comparatively slower than other healthcare 
areas [2,3]. The distinguishing pharmacokinetic hurdle [4] to drug development for CNS 
disorders is the BBB [3], which effectively blocks nearly all nonpolar compounds larger 
than ~500Da from entering neural tissue [5]. Due to this prevalent role in drug 
development, innovative preclinical models of the BBB are in high demand. BBB models 




induced by chemical and physical stimuli; and to (2) predict the rate of delivery of 
compounds across the BBB. The first application is extremely useful for basic research 
on BBB physiological mechanisms, and to study the BBB’s role in CNS disease 
progression [6]; the second application can be used to test the passage of novel drugs [7] 
or drug delivery vehicles [8] across the BBB during stages of prescreening and 
optimization of CNS treatments prior to animal and clinical studies [9]. This dissertation 
aims to include feasibility of the use of the innovative system for both of these 
applications within its scope. 
In vitro models are a valuable precursor to animal models due to lower cost, time, 
and ethical constraints [10], and enable more focused, controllable, and repeatable 
experimentation, as well as more massively-parallel environments. The validity of an in 
vitro model is dependent on how closely it reproduces the key physiological 
characteristics of its in vivo archetype. The key characteristics of the BBB include: 
Structurally, (1) a contiguous monolayer of endothelial cells containing strongly 
expressed tight junctions [11]; (2) astrocytes in close contact with the endothelial 
monolayer, which play a key role in modulating barrier function through cell signaling 
from endfoot processes [12]; functionally having strong expression of (3) membrane-
bound transport components for receptor-mediated transport and efflux transport [13]; a 
microenvironment experiencing (4) fluidic shear stress, which is known to have a 
mechanotransductive effect on endothelial cell phenotype [14,15]; Model conditions 
should show highly (5) selective permeability from the constituted structures to dissolved 
compounds; and (6) maintenance of high electrical resistance indicating the contiguity of 





rapid measurement of these physiological conditions is an important component to a valid 
BBB model. This is particularly the case for trans-membrane properties, thus an effective 
BBB model must allow reliable measurement of tracer compound permeability and trans-
endothelial electrical resistance (TEER). 
The commercially-available current state-of-the art in vitro models comprises a 
simple transwell insert [16]. Transwell inserts comprise of a porous membrane attached 
to a cup-shaped insert for placement in multiwell plates of multiple sizes. However, they 
are limited to represent only static environments, without continuous luminal flows. 
Luminal flows are known to cause fluid shear stress [5] that imposes 
mechanotransductive effects on endothelial cell phenotypes in vitro and in vivo [17], thus 
influencing a myriad of molecular pathways [18] activated via membrane-bound 
receptors [19], inducing proliferative responses including tight junction proteins [20], 
membrane efflux transporters [14], and cytoskeletal restructuring and cell reorientation 
[15] in a manner dependent on flow direction [21]. Thus, a truly representative in vitro 
model should have physiologically relevant flow conditions.  
In 1996, a dynamic in vitro BBB (DIV-BBB) [22-24] model was developed which 
utilizes hollow fibers to mimic BBB architecture and flow conditions. However, the DIV-
BBB has wall thickness (150µm) significantly higher than transwell membranes (10µm), 
discouraging cell-cell interaction and decreasing background permeability, take 
significantly longer (~3x) to reach steady-state barrier permeability [10,22] than 2D 
models, and lack the potential for integration of biosensors and compartmentalized or 
parallel array setups due to the simplicity of their design and fabrication as simple hollow 





than 10x larger than brain capillaries, failing to accurately represent in vivo  flow 
conditions. 
To address these short-comings of existing systems, this dissertation presents a 
microfluidic in vitro BBB model (µBBB) [25] that includes several practical advantages: 
(A) Significantly lower costs, timescales, and ethical issues than in vivo studies; (B) 
Massively-parallel, controlled and repeatable environments, and easier elucidation of 
molecular mechanisms than in vivo models; (C) Dynamic microenvironment providing 
shear stress stimulation to cultured endothelial cells, allowing controlled delivery of test 
compounds and improved permeability analysis compared to in vitro static models; (D) 
Much thinner culture membrane, decreasing the distance between co-cultured cells for 
compound diffusion, compared to in vitro DIV-BBB  models. (E) Smaller functional 
volumes for quicker media exchange, material conservation, and scales closer to true in 
vivo dimensions; (F) A 2D culture surface allowing complete initial seeding and shorter 
times to steady-state barrier resistance for a more rapid turn-around time, shortening 
experiments and allowing a more high-throughput approach to experimentation.  
The impact of this dissertation involves development of an innovative platform 
for BBB modeling with the aforementioned practical advantages, and characterization 
and validation of such a system in both scientific and engineering aspects for use in basic 
research and pharmaceutical drug development for the following two applications: (1) 
The system was developed and utilized to test responses of the cultured cells to chemical 
and physical stimuli, including chemical stimulation [26] and shear stress [27]. (2) The 
system was also used for proof-of-concept as a drug delivery test platform for predicting 





validity of a microfluidic BBB platform for use by both the scientific community, to study 
BBB physiological functions and responses to various chemical or physical stimuli in 
basic research, and the industry community, for prescreening of BBB clearance of novel 
pharmaceuticals as a predictive tool. It is our educated opinion that microfluidic systems 
will inevitably be commercialized for heavy use in these applications in the coming years, 
and the work in this dissertation is intended as the launching point. 
 
1.2 Summary of Innovation 
This dissertation reports the first published chip-based microfluidic cell culture 
model for the BBB [28], the first published microfluidic platform allowing simultaneous 
testing of endothelial cell trans-membrane and morphological properties under multiple 
distinct shear stresses [29], and the first multidrug (>3) correlation of a microfluidic BBB 
model with in vivo brain penetration results [30]. The multilayered microfluidic device 
(MMD) comprises two base polydimethylsiloxane (PDMS) substrates, two glass layers, 
and a free-standing porous membrane [31] fixed between the PDMS layers. It houses two 
perpendicularly-crossing channels to introduce dynamic flows, and the functional barrier 
area is located on free-standing membrane at the channel junction, enabling the ability to 
conduct flow-based permeability assays. This is particularly advantageous because it 
allows steady-state concentrations to be maintained in both the luminal and abluminal 
chambers, whereas static transwell concentrations gradually change over time as they 
reach equilibrium, reducing the accuracy of permeability calculations. Commercial 
electrode sticks have been used to measure TEER in conventional microfluidic systems 





thin-film electrodes, fixing the distance between electrodes for measurement 
repeatability. Nondestructive microscopy of the system is also possible due to 
transparency of the PDMS substrate. In addition, we developed a novel experimental 
design employing a parallel array of the luminal channels containing endothelial cells, 
allowing unprecedented simultaneous measurement of endothelial cell trans-membrane 
and morphological properties under varying magnitudes of shear stress. In summary, 
these engineered innovations of the novel platform enable scientific advantages, by 
allowing mimicry of the dynamic environment found in vivo, as well as practical 
advantages, by providing greater experimental control, high tunability of model 
conditions, better measurement of BBB functionality, material conservation, and cost. 
 
1.3 Research Objectives 
The objective of this dissertation is to introduce, characterize, and validate the 
first microfluidic BBB, was largely accomplished through three distinct research phases, 
which are respectively reported in Chapters 3-5. The forthcoming chapters will be 
structured as follows, describing the complete scope of this dissertation. 
Chapter 2 provides the background necessary for understanding the studies 
described in the following chapters, including (1) underlying biology of the BBB, (2) 
review of previous models of the BBB, (3) review of microfluidics systems and 
fabrication methods used in this dissertation, (4) characteristics of the BBB model used 
in this dissertation, and (5) methods of model validation used in this dissertation. 
Chapter 3 describes initial development and characterization of the µBBB model 





as a low-cost, polymeric alternative to previous dynamic hollow-fiber based systems, 
with particular discussion comparing these systems. The foundational concepts of the 
µBBB are covered in this chapter, and the methods of observing trans-membrane 
properties were developed. Cell lines bEnd.3 and C8-D1A were used in this study, and 
the effects of chemical modulation (histamine, pH elevation) on trans-membrane barrier 
properties (TEER, tracer permeability) were observed. 
Chapter 4 describes the development of a modified version of the device designed 
for observation of quantitatively-dependent effects of shear stress stimulation on 
endothelial cell physiological properties, in an unprecedently high-throughput manner. 
This was done to test for any flow-rate limitations for the BBB model with the bEnd.3 
cell line, and to observe mechanical modulation effects on both trans-membrane barrier 
properties (TEER, tracer permeability) and morphometric properties (cell alignment, 
shape), as well as on BBB protein expression (zonal occludin-1, P-glycoprotein). 
Chapter 5 describes a proof-of-concept study of the system as a predictive tool for 
drug clearance, by running 7 CNS-targeting drugs currently under development through 
the BBB model prepared with bEnd.3 cells in monoculture and in co-culture with C6 
astrocytes. Concentration-specific cytotoxicity of these compounds were measured to 
establish acceptable permeability assay concentrations, and permeated concentrations of 
the drugs were measured with chromatographic methods. Permeability results were 
compared in vivo data from literature to confirm in vivo correlation.  
Chapter 6 summarizes the project’s impact, and stature within the current, new 
body of microfluidic BBB platforms, presents some unpublished results relating to P-





and C6, and discusses several future directions and applications for the model 
characterized in this dissertation. 
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2.1 Structure and Function of the Blood-Brain Barrier 
The distinguishing characteristic in the process of drug delivery to the central 
nervous system (CNS), consisting of the brain and spinal cord, is the blood-brain barrier 
(BBB). Around the end of the 19th century, it was first noted by Paul Ehrlich that 
intravenous injections of dye elucidate a clear lack of staining in the CNS [1]. A few years 
later, the term BBB was first coined by Lewandowski et al. when studying the limitations 
of perfusion of potassium ferrocyanate into the CNS [2]. The invention of the electron 
microscope in the 1960s allowed the anatomical structure of the BBB to be observed and 
described using intravascular horseradish peroxidase injections [3], rapidly progressing 
our understanding of the structure and function of the BBB.  
 
2.1.1 Introduction to the Neurovascular Unit 
The BBB effectively restricts virtually all molecules except small and lipophilic 
ones – only small lipophilic molecules with molecular weights below ~500 Daltons 
typically cross the BBB freely [4]. The presence of this uniquely restrictive barrier to 
compounds in the CNS exists primarily for 4 physiological reasons: (1) Maintenance of 




controlling nutrient supply in the brain, and (4) directing inflammatory responses 
according to changes in the local environment [5]. 
 
2.1.2 BBB Physiological Features 
The physical characteristics of the BBB are dictated by a dynamic interaction 
between multiple cell types, primarily the brain endothelial cells lining the capillaries in 
the brain. Brain endothelial cells are distinct from peripheral endothelial cells in several 
ways, including reduced pinocytic activity [6], lack of fenestrations [7], higher 
mitochondrial density [8], and higher expression of membrane transporters [9]. These 
distinct characteristics are highly dependent on the interactions with surrounding glial 
cells, thus the neurovascular unit is considered to consist of multiple types of cells. 
Anatomically, the neurovascular unit is comprised of both the endothelial cells and the 
surrounding pericytes and astrocytes [10], though there is evidence that neurons may also 
play a role in endothelial phenotype as well [11] (Figure 2.1). 
The BBB’s barrier properties are primarily governed by a combination of the 
physical barrier provided by the tight junctions, the transport barrier provided by the 
membrane transport efflux mechanisms including ATP-binding Casette transporter 
proteins such as P-gp or other multidrug resistance proteins (MRPs) such as breast cancer 
resistance protein (BCRP) [12], as well as a metabolic barrier component. Additionally, 
the BBB maintains the ionic composition of the brain for optimal synaptic functions of 
neurons, largely via specific ion channels and transporters [13]. Thus, the BBB is 
important for protecting the CNS from neurotoxic and xenobiotic compounds, in addition 






Figure 2.1 Structure of brain capillaries. Structurally, brain capillaries are made 
up of brain microvascular endothelial cells the endfeet of astrocytes, and pericytes within 
the basement membrane. In addition to tight junctions between endothelial cells, the 
blood-brain barrier is functionally controlled by ATP-binding cassette (ABC) 
transporters such as p-gp, or other multidrug resistance proteins (MRPs) such as breast 
cancer resistance protein (Bcrp). Figure from Fricker [12]. 
 
2.1.2.1 Role of Endothelial Cell Tight Junctions 
 The paracellular route for compounds to pass the endothelial cell layer is primarily 
regulated by tight junctions, a highly complex structural assembly of proteins [14] which 
make up the extracellular space between adjacent endothelial cells, effectively abolishing 
aqueous diffusional pathways between the blood and brain [15,16]. Endothelial cell tight 
junctions consist of transmembrane proteins [17,18], largely occludins [19], claudins 
[20], and junctional adhesion molecules (JAMs). These compounds are directly linked to 
cytoplasmic proteins known as zonal occludins, which are further linked to the actin 
cytoskeleton [21]. Thus, the zonal occludins (ZO-1, ZO-2, ZO-3) regulate the 





effectiveness of tight junctions in barrier function, and are most commonly studied 
(particularly ZO-1) for validation of BBB properties because they are specific markers 
for tight junctions and act as an intermediate molecule in the tight junction complex. 
 In addition to their role as structural barriers, tight junctions have also been 
observed to be dynamic signaling complexes, involving control of gene expression, cell 
proliferation, and differentiation in a bi-directional manner [22]. For example, with this 
mechanism, tight junctions coordinately receive and transmit signal molecules of the Rho 
class with intracellular mechanisms [23], signaling routes mainly involving protein 
kinases activated through phosphorylation cascades [24]. Thus, the role of tight junctions 
in BBB function likely extends beyond guarding the paracellular route for compounds. 
 
2.1.2.2 Role of Membrane Transporters 
P-glycoprotein (P-gp), often referred to as the primary multidrug resistance 
(MDR) protein, is an efflux transporter found on luminal endothelial membranes as well 
as at astrocyte processes in the brain [25]. While the paracellular route for compounds is 
guarded by tight junctions, the transcellular route is guarded largely by ABC transporters 
such as P-gp [26] or Bcrp, effectively expelling a large variety of compounds into the 
luminal space as a key component in BBB homeostasis. For this reason, P-gp expression 
is considered to be an essential measure for evaluating cell constituents in in vitro BBB 
models [27]. 
Also relevant to drug delivery through the BBB is the presence of transporters on 
endothelium which move the opposite direction from P-gp. These are particularly 





cannot enter paracellular routes to enter the brain through transcellular routes [10]. 
Among the best known and characterized are transferrin receptor [28], glucose carrier 
GLUT-1 [29], and amino acid transporter L1 [30], which exist in higher concentrations 
than peripheral endothelial cells, providing potential delivery routes to the brain for 
tailored macromolecules [31]. To date, such macromolecules have not proven to reach 
the CNS in effective pharmacological concentrations, though such routes are promising 
for future clinical application, and future study testing the effectiveness of such 
macromolecules for BBB passage in in vitro models should include characterization of 
the presence of the target receptor in the BBB model in use. 
 
2.1.2.3 Role of Astrocytes 
As early as 1967, it has been predicted that astrocytes play a major role in inducing 
BBB phenotype and specialization [32]. Astrocyte endfeet have been observed to cover 
the majority of the abluminal surface of brain endothelial cells [33], secreting a number 
of inducing factors, such as transforming growth factor-β, glial-derived neurotrophic 
factor (GDNF), basic fibroblast growth factor, and angiopoetin 1 [34]. These processes 
influence a number of mediating compounds in BBB function [35], including effects on 
both the paracellular compound pathway, tight junction expression [36], and effects on 
the transcellular pathway, membrane-bound transporters such as P-gp [37] and GLUT-1 
[33]. Astrocytes have been seen to produce factors inducing development of tight 
junctions through these processes, leading to induction of transcytotic mechanisms such 
as transferrin receptor [38]. BBB characteristics have even been induced in non-brain 





Furthermore, endothelial cells have been shown to produce factors to facilitate astrocyte 
differentiation [40]. It is clear that the interaction between these two cell types are highly 
important to BBB physiology, therefore they are included in most in vitro co-culture 
models. 
 
2.1.2.4 Role of Shear Stress 
 The exposure to physiological shear stress plays a critical role in modulating 
endothelial cell morphology [41]. Endothelial cells cultured under shear stress show a 
number of physiological characteristics more representative of in situ [42], such as an 
abundance of endocytic vesicles, microfilaments, and clathrin-coated pits [43]. A number 
of membrane-bound proteins, including integrins [44], caveolae [45], G proteins [46], 
and ion channels [47,48], have been shown to be involved in mechanotransduction of 
shear stress into pleiotropic physiological responses, initiated by downstream signal-
regulated kinases [49]. Among the physiological functions affected are: (1) production of 
substances related to vasoactivity and cell adhesion [50,51], (2) increased expression of 
tight junctions [52], (3) increased cell survival [53], (4) energy metabolism [54], and (5) 
membrane transport systems [42]. Accordingly, these physiological responses have an 
effect on barrier activity; therefore, reconstituting a high-shear stress environment is 
essential for a truly representative BBB model. 
 
2.2 Traditional Models of the Blood-Brain Barrier 
 The two primary classifications of BBB models are in vivo, studies with complete 





laboratory. While all aspects of the in vivo system are yet to be reproduced in an in vitro 
model [55], they have contributed significantly to our current understanding of 
endothelial transport and regulation. Indeed, the principle advantages of in vitro models 
include (1) higher capacity and higher throughput, (2) lower costs and reagents required, 
(3) the ability to quantify compounds directly in physiological buffers, (4) feasible 
identification of cell toxicity, (5) and lesser ethical constraints [56]. Nevertheless, to 
increase their experimental advantage, in vitro models must be developed to mimic the 
in vivo microenvironment as closely as possible to ensure their predictive accuracy. 
  
2.2.1 In Vivo Models 
Direct in vivo brain uptake techniques provide reliable characterization of drug 
BBB penetration [57]. Studies of in vivo brain penetration look at both the permeability 
surface area product PS, as well as brain uptake ratio Kp, which includes equilibration of 
the compound in neural tissue over time [58]. Kp is based on the ratio of brain and plasma 
concentrations under steady-state biodistribution [59]. PS is particularly advantageous in 
terms of permeability information, because it is not compromised by drug metabolism, 
protein binding, or nonspecific brain binding [60]. PS is measured by perfusing the brain 
directly with the tracer via the carotid artery, allowing short-term measurement of 
permeability. However, PS is a highly technically demanding product to measure, and is 
considerably lower-throughput than Kp, often only measured in late stages of compound 
development. Though these methodologies are comparably low-throughput compared to 






In addition to full-animal in vivo experiments, isolated brain capillaries from 
various sources, including human and bovine, rat, rabbit, and pig [61], have been studied 
ex vivo for studying drug accumulation, transporter activity , and gene expression [62,63]. 
However, such ex vivo studies are technically demanding and ethically limiting, the 
preparation procedures tend to modify barrier functions [64], while access to the luminal 
surface of microvessels is nearly impossible [65]. Thus, the development of in vitro 
models was deemed necessary. 
 
2.2.2 In Vitro Models 
  Cells used in in vitro-based BBB models are commonly derived from one of 
many mammalian species, including bovine, porcine, rat, murine, or human [66]. High 
costs and laborious, time-consuming isolation procedures lead to the necessity for use of 
immortalized cell lines. These cell lines have the advantage of undergoing a large number 
of passages without any change in phenotype, and enable ultra-high yield and 
homogeneity [67]. However, these cell lines have a disadvantage in that they typically 
show higher leakiness and lower expression levels of tight junction and transporter 
proteins than primary cells [55]. Overall, the utilization of immortalized cell lines have 
been widely accepted for in vitro models due to high consistency from passage to passage 
as well as in intralaboratory-comparison, highly repeatable physiological behaviors and 








2.2.2.1 Transwell Systems 
 The current state-of-the-art for BBB models, and epithelial/endothelial cell 
culture models in general, is the simple transwell system (Figure 2.2A). Transwells are 
comprised of porous inserts for well plates, available in many sizes (6-, 12-, 24-, or 48-
wells). These systems are unique over the universal polystyrene-surface cell culture 
vessels in that they allow interaction between multiple chambers through a porous barrier 
which restricts migration of cells of a certain size, while allowing all components of the 
cellular media [69]. Another, perhaps more significant way these models transcend basic  
Figure 2.2 Traditional in vitro BBB models. (A) The majority of in vitro BBB 
models use transwells, in static condition with a porous insert in a multi-well setup. (B) 
Hollow fiber bundled systems represent a dynamic in vitro for introducing flow-based 










cell culture vessels is that they allow modeling of cooperative interaction between the 
multiple cell types, while keeping the cells of different type isolated from each other 
physically [70]. However, the overly simplistic transwell platform lacks the exposure to 
intraluminal shear stress. This is critical for the vascular endothelium to develop and/or 
maintain intrinsic BBB properties observed in vivo; therefore, integration of a shear stress 
component to the system is crucial. In addition, experimental control over delivered 
permeability compounds is insufficient for accurate permeability measurement, as 
concentrations in the luminal and abluminal chambers change over time, contradicting 
assumptions of linearity of membrane flux during permeability assays. 
 
2.2.2.2 Dynamic In Vitro BBB Models 
 To enable the introduction of flow into BBB cell culture models, several types of 
microfluidic systems have been utilized. The cone-plate apparatus represents the first 
attempt [71], comprising a rotating cone opposite an endothelial cell monolayer. The 
angular motion of the cone translates to shear stress exerted on the cell monolayer; 
however, the shear stress is not entirely uniform along the radius of the cone, resulting in 
an uneven magnitude of shear stress applied to the cells. In addition, such systems did not 
contain porous substrates for permeability studies or compartmentalized co-cultures. 
Nevertheless, many early studies of shear stress effects on cells were conducted with these 
systems [72]. 
 Artificial capillary-like structures known as hollow fibers, which are made from 
thermoplastic polymers such as polypropylene or polysulfone, have been adapted to 





BBB (DIV-BBB) systems (Figure 2.2B) [73]. In macroscopic terms, these hollow fiber 
bundles resemble vessel structures, though at a 10x larger scale. Bundles are typically 
seeded in the interior with brain microvascular cells, with astrocytes in the exterior space 
of the bundles, allowing study of physiological response of cells under tunable levels of 
shear stress [74]. However, due to the 3D structure of these systems, cell growth cannot 
be evaluated directly with microscopy, and they take significantly longer to reach full 
confluence than 2D systems. The thicknesses (200 µm) of the hollow fiber walls are far 
higher than track-etched porous membranes, by more than a factor of 10x. This increase 
in distance makes the presence of cell-cell interaction via migration of astrocyte processes 
through the porous substrate far less likely [75]. Finally, in comparison to these hollow 
fiber systems, much smaller systems with lesser cell and reagent consumption and faster 
turn-around times can be achieved with microfluidic systems containing tailored 2D 
culture surfaces and integrated sensors. 
 
2.3 MEMS and Microfluidics 
 Microfabrication technology, particularly microelectromechanical systems 
(MEMS) allow the development of a more innovative BBB model. MEMS technologies 
have stemmed from the methodological foundations provided by the integrated circuit 
industry, allowing development of mechanical systems at an increasingly smaller scale. 
Thus far, microfluidic systems have been employed primarily in industry for the 
applications of analytic devices, miniaturized sensors, flow cytometry, and disposable 
HPLC chips [76]. More recently, these techniques have garnered increased interest in the 





dimensions with high resolution/sensitivity, (2) incorporation of sensing and actuating 
function, (3) ease to study interaction of molecules with cells, (4) minimal invasiveness, 
(5) high portability, (6) shorter analysis time, and (7) high-throughput experimentation 
[77]. 
 
2.3.1 Previous Microfluidic Cell Culture Systems 
In terms of flow-based cell culture systems, microfluidics hold several practical 
advantages over macroscale flow systems, including efficient exploitation of mechanical 
forces, dominance of viscous and diffusional forces, rapid turn-around times, and low 
costs [78]. Microfluidic systems permit spatial confinements resulting in biochemical 
gradients and diffusive profiles more representative of the in vivo microenvironment. The 
advent of microfluidics have generated unprecedented opportunity to study and use 
biological cells in new, uniquely tailorable microenvironments in a highly parallel 
experimental manner [79], enabling generation of abundant information. Microfluidic 
platforms have seen considerable progress for the application of liver cell culture and 
study [80,81]. Because of the small dimensions and resultantly laminar flows inherent to 
microfluidic platforms, they are particularly well suited for modeling vascular systems in 
a high-throughput and environmentally relevant manner; therefore, such systems have 
been utilized for reconstituting vascular systems [82] and probing artery function [83], 
proving useful for studying blood circulation dynamics [84], behaviors of vascular 
endothelial cells under shear stress [85], angiogenesis dynamics [86], and vascularization 
of tailored scaffolds [87]. However, the system described in this dissertation represents 





2.3.2 Fabrication Methods 
 Techniques used in this dissertation involve both hard (silicon, glass) and soft 
(polymer) micromachining methods. While hard micromachining has its roots in the 
integrated circuits industry [89], soft lithography methods have been developed more 
recently, based on fabrication of polymeric substrates [77].  
 
2.3.2.1 Hard Micromachining Methods 
 The primary thin-film deposition method used in this dissertation is sputtering 
[90]. Sputtering has some advantages over other thin-film deposition methods, such as 
evaporation and chemical vapor deposition (CVD): A wide variety of materials are 
feasible for deposition, and the Denton Discovery 18 system available in our fabrication 
facility has multiple targets, allowing three metals to be deposited in a single pump-down 
process. Second, there is relatively low energy and temperature of the sputtered atoms 
compared with evaporation, which is particularly advantageous for the lift-off process, in 
which the films are laid directly onto photoresist, which tends to be distorted at high 
temperatures. However, even with this low-temperature process, distorting does occur at 
high enough power; therefore, sputtering processes in this dissertation were conducted at 
no higher than 50W power. 
 Lithography is used to transfer a master pattern onto the substrate surface. 
Photolithography is the predominant method for microfabrication, where UV light 
passing through a mask is used to define the etching pattern on the substrate. The 
lithography method used for thin-film patterning in this dissertation is the lift-off process, 





film deposition, used the following steps: (1) Generation of the 2D pattern on computer-
aided drafting (CAD) software; (2) Fabrication of the mask for these processes were 
generated on a quartz plate with a chromium absorber metal by e-beam lithography, 
which has a higher resolution than photolithography; (3) Deposition of the photoresist on 
a cleaned, prepared glass substrate. A lift-off photoresist (LOR-10B) in addition to 
patterning positive photoresist (S1813) was used, in that the material is dissolved by the 
developer when exposed to UV light. Spin-coating of the viscous photoresist solutions 
was used to uniformly deposit the materials on the substrate, with speeds ranging from 
1500-4000 RPM; (4) Soft-baking of the photoresist on a hotplate (190°C for LOR-10B, 
110°C for S1813) to ensure success of the pattern transfer; (5) UV exposure through the 
aligned photomask. A UV lamp projects light through the mask to the substrate in hard 
contact at the correct dose to achieve proper pattern development; (6) Wet development 
of the exposed photoresist using liquid developer (MIF-300); (7) Thin-film layer 
deposition. The sputtering process is low-temperature enough to prevent distortion of the 
photoresist pattern; (8) Lift-off using acetone under sonication. This process results in the 
final patterned layers of metal films on the glass substrate. 
 
2.3.2.2 Soft Micromachining Methods 
 In contrast with traditional hard materials, polymers are inexpensive, easy to 
handle, have highly tunable mechanical properties, and are largely biocompatible. The 
silicone-based elastomer polydimethylsiloxane (PDMS) has been adopted as the most 
popular bioMEMS polymer substrate due to its highly suitable combination of physical 





(2)  superior conformability to other surfaces for large-scale integration [92]; (3) good 
sealing with itself and other surfaces, both reversibly and irreversibly [93]; (4) highly 
transparent (5) highly permeable to gases [94], facilitating cell-based applications. The 
PDMS material used in this dissertation was the Sylgard 184 (Dow-Corning), which cures 
quickly at a mixed ratio of 10:1 at any temperature higher than about 60°C. 
Due to the malleable characteristics of uncured PDMS, an enormous variety of 
shapes can be defined by use of replica molding, enabling high-fidelity 3D pattern 
generation with exceptionally high aspect ratios [89]. The replica molds for this 
dissertation were generated using photolithography. In contrast with the lift-off process 
used for hard micromachining in this project, the replica mold was generated from SU-8, 
which is a negative photoresist, in that the material is solidified by the developer when 
exposed to UV light. SU-8 is composed of EPON SU-8 resin, and a photosensitizer triaryl 
sulfonium salt [95]. Due to the epoxy resin’s high stability and high cross-linking density, 
extremely thick coatings can be achieved. One of the thickest varieties (SU-8 2075) was 
used in this project to enable the 200 µm thick microfluidic structures. 
  
2.3.2.3 Bonding Methods 
 Soft substrate bonding is one of the most critical steps for generation of multi-
layered microfluidic device. Hard substrate bonding (silicon-silicon, silicon-glass, or 
glass-glass) were not required for the structures used in this dissertation. The particular 
soft-substrate bonding methods under concern in this dissertation were PDMS-PDMS, 
PDMS-glass, and PDMS-polycarbonate membrane. Indeed, errors with bonding are 





important design consideration for microfluidic devices is the method of bonding. The 
use of oxygen plasma allows simple oxidation of the surface of both PDMS and glass 
substrates to generate irreversible siloxane bonds (Si-O-Si) for a strong, reliable bond 
[97].  
However, the need to bond the polycarbonate porous membrane between the 
PDMS substrates limits the feasibility of the plasma oxidation method. More recently, a 
method was devised where PDMS prepolymer is used as a mortar to enable bonding of 
porous membranes into layers of PDMS [98], and this method was used for the study 
presented in Chapter 3. The PDMS prepolymer mixture is diluted in toluene to 
significantly reduce the viscosity of the mixture in a tunable manner, and is spin-coated 
onto a Si wafer, which is then pressed to the channel substrate to generate a sufficiently 
thin layer of PDMS prepolymer to allow bonding of the membrane without clogging the 
channels. The assembly is pressed together and cured in an oven, generating a strong 
bond. However, this method requires both heat and pressure, making sufficiently uniform 
application of pressure to obtain a complete seal around the channel structures, while 
preventing deformation of the channel structure or the membrane, quite tedious for larger 
structures leading to frequent failures; therefore, a different method was adopted for the 
subsequent studies. This method utilizes 3-amino-propyltriethoxysilane (APTES), a 
biocompatible surface treatment, to modify the surface of the membrane, allowing plasma 
activation [99]. Following ~20 min of surface activation in a 5% aqueous solution at 
80°C, the membrane and PDMS substrates are activated with oxygen plasma, and a 
strong, irreversible bond is achieved at room temperature in the same manner as 





membrane is dissolved in ethanol. Indeed, this method yielded a more reliable bond than 
the prepolymer mortar method, as indicated by a significant reduction in the occurrence 
of leaks. 
 
2.3.2.4 Packaging and Preparation 
 Packaging methods used in this dissertation pertain primarily to postassembly 
preparation. A Disco DAD641 dicing machine was used to cut the glass wafers used for 
electrode inserts into rectangular shapes to be embedded into the channel layers. Prior to 
bonding, a biopsy punch with 2mm diameter was used to core holes for the inlets and 
outlets. Following bonding, inlets and outlets were prepared for connection to tubing 
assemblies. Needles with the sharp edge cut flat were used to connect tubing to the chips 
due to their low volume, and were embedded inside 25 µL pipette tips to ensure secure 
connection to the inlet holes. Dow Corning 734 flowable sealant was used for securing 
inlet connectors due to its high compatibility with PDMS, and lack of any chemical 
reaction to ethanol, which is used heavily during the sterilization process. 
 
2.4 In Vitro Model Characteristics 
As it is well known that no existing in vitro BBB model has mimicked all BBB 
functionalities [100], researchers in development of BBB in vitro models aim to achieve 
the most relevant features of the BBB for the particular aim of investigation [101]. 
Nevertheless, the ultimate goal in the field is to achieve as many BBB characteristics as 
possible, as is our goal in this dissertation. Inclusion of the right model characteristics are 





2.4.1 Constituent Cell Types 
The current standard is co-culture systems with endothelial and glial cells. A third 
cell type, the pericyte, is present in vivo and covers approximately a quarter of the 
abluminal endothelial surface, playing a role in endothelial proliferation and 
inflammatory processes [102]. Difficulties in isolating this cell type have limited their 
use in in vitro models. For this dissertation, we have focused on the two standard cell 
types, brain endothelial and glial cells. 
Though advantageous in initial cell phenotype, primary cells are difficult and 
costly to obtain, and generally lose BBB characteristics after only a few passages, while 
also being subject to ethical limitations. Conversely, immortalized cell lines retain 
consistent physiological and morphological characteristics over as many passages as 
needed. This is due to the immortalization process through viral transformation. These 
provide advantages in experimental consistency, despite their drawbacks in cell 
phenotype. 
Many immortalized cell lines have been used in BBB models, including brain 
endothelial cells of bovine, porcine, murine, or rat source,  MDCK cells, and CACO-2 
cells [103]. Popular endothelial cell lines have been used, including the RBE4 from rat 
origin [104] or the hCMEC/D3 cell line derived from human origin [105]. In addition, 
the highly characterized human epithelial cell line Caco-2 has been used in BBB models 
[106], despite heavy differences from brain endothelial cells in terms of cell phenotype 
[107]. For this dissertation, we opted to use the bEnd.3 immortalized murine cell line 
because it has been shown to express levels of ZO-1, claudin-5, and occludin comparative 





proliferation. For co-culture, the immortalized rat glial cell line C8-D1A was used in the 
initial characterization study. However, its proliferative properties were inferior to 
bEnd.3, thus subsequently the C6 glial cell line was used because it was commonly used 
in previous co-culture BBB models [110,111] and to generate astrocyte-conditioned 
medium [112], and because its proliferative properties were comparable to bEnd.3. 
 
2.4.2 Porous Membrane 
The most common materials for track-etched porous membranes used in BBB 
models are polycarbonate and polyethylene terephthalate (PET), each with their own 
advantages. Polycarbonate membranes have lower nonspecific binding properties and 
thus less interference with testing compounds, whereas PET membranes are transparent, 
allowing light-based microscopic observation of cells adhered to them [113]. Another 
influential property is pore size, where pores of 0.4µm have been seen to produce highest 
trans-endothelial electrical resistance (TEER) with otherwise similar conditions [114]. 
Furthermore, 0.4 µm pore size has been shown to restrict astrocyte cell bodies from 
migrating through the membrane, while allowing end-feet to pass through the pores to 
interact with the adjacent endothelial cells [115]. Conversely, 3.0 µm pores prompt 
migration of astrocyte growth on both sides of the membrane, and clogging of pores, 
preventing passage of astrocytic soluble factors [116,117]. For these reasons, 
polycarbonate membranes of 0.4 µm pore size (provided by Corning) were used in this 
dissertation, with a 10 µm membrane thickness, and nominal pore density of 1x108 






  2.4.3 Adhesion-Promoting Treatments 
Coating of the membrane culture surface is a key model condition for achieving 
optimal model performance, particularly in microfluidic models where adhesion to the 
substrate is a potential issue. These protein coatings are intended to mimic the basal 
lamina, a key extracellular component in the BBB [118]. The major components of the 
basal lamina include type IV collagen and fibronectin [119], which are commonly used 
in previous BBB models as well as in this dissertation. What concentrations should be 
used for these coatings have not been clearly established [120]; therefore, some trial-and-
error experimentation was required for this study. For example, in Chapter 3, lower 
concentrations were used (10 µg/mL) during the coating step, and was sufficient for the 
low flows used in the study. However, increasing concentrations of each protein to 100 
µg/mL for coating in Chapter 4 enabled optimal adhesion of endothelial cells at 
comparatively higher flows (several orders of magntitude), and this coating scheme was 
also used in Chapter 5. 
 
2.4.4 Cellular Media 
 An advantage of immortalized cell lines is that they perform consistently well 
without media supplementation, and the same media formulation was used for all studies 
in this dissertation: A 50/50 mixture of Dulbecco’s Modified Eagle Medium (DMEM) 
and Ham’s Nutrient Mixture F12, supplemented with 0.365 g/L L-glutamine and 5% fetal 
bovine serum (FBS). In addition, penicillin/streptomycin solution and amphotericin B 






 Many BBB models have opted to replace the presence of astrocytes with 
astrocyte-conditioned medium, or media bathing astrocyte cell cultures to allow it to 
contain astrocyte-derived soluble factors secreted by the cells [121]. These astrocyte-
conditioned media have been seen to modulate barrier properties relating to expression 
of tight junction [122] and efflux transporter proteins [123]. Other supplementation 
includes the addition of hydrocortisone to the cell culture media following seeding, which 
has been seen to benefit the formation of barrier properties, though the exact mechanism 
by which hydrocortisone does this remains largely unclear [124]. Another additive 
commonly used to purify primary cells is puromycin, which eliminates nonendothelial 
cells from the cultured cells [125]. 
 
2.4.5 Microfluidic Structures 
The use of microfluidics in this dissertation enabled the application of shear stress 
to the cells in a highly controllable manner. The microfluidic structure itself went through 
a number of changes depending on the aims of the study itself. All mask designs were 
generated using SolidWorks software. For consistency, the depth of the microfluidic 
structure was kept at a constant 200 µm thickness. Slight variations of SU-8 film 
thicknesses occur due to imperfect levelling of the hot-plate and occasional presence of 
bubbles during the sot-bake process [126]. To reduce the occurences of these bubbles, a 
glass dish was placed over the hot-plate during the soft-bake process following initial 
spin-coating, and the film was deposited in two 100 µm layers instead of a single 200 µm 
layer. The degree of error allowed during fabrication of the silicon replica molds was 10 





Profilometer, and only molds were used where all measurements were between 190-210 
µm. 
All flow in all versions of the microfluidic structures used in this dissertation are 
completely laminar [127] and thus viscous-dominant, where dissolved particle motion is 
dominated by diffusion, as in capillaries: The Reynolds number for a rectangular channel 
is calculated as: 
 
𝑅𝑅𝑅𝑅 = 2𝜌𝜌𝑉𝑉𝑎𝑎𝑎𝑎𝑎𝑎(𝑤𝑤ℎ)
𝜇𝜇(𝑤𝑤 + ℎ)  (2.1) 
where ρ and µ are density and viscosity, respectively, and w and h are channel width and 
height, respectively. Based on this equation, the lowest aspect ratio channel used in this 
dissertation (and highest Reynolds number) of dimensions 100µmX400µm, has a 
Reynolds number of ~2.3s/cm*Vave, where Vave is the average velocity. Thus, the 
minimum velocity for transition to turbulent flow is ~1000 cm/s, several orders of 
magnitude higher than practical flow-rates used in this dissertation; therefore, it is a valid 
assumption that flow is completely laminar for all experiments. 
 
2.5 Methods of Model Characterization 
This dissertation uses previously established methods of characterization to 
validate the model in each of the studies described in the forthcoming chapters. The 
primary methods of model characterization are TEER and compound permeability, as 
they are direct representations of monolayer tightness and compound diffusion, 
respectively. Additionally, to look at cell morphologies and specific expression of BBB 





more indirect measures of barrier function. Finally, to characterize flow characteristics of 
the microfluidic component of the model, computational simulations are used. The 
specific methodological procedures of each of these techniques for the studies in Chapters 
3-6 will be described in greater detail as it pertains to the specific study. 
 
2.5.1 TEER Measurement 
TEER of endothelial cell monolayers is feasible because the cells may be 
considered to have a level of resistance to ionic movement through the paracellular 
pathways (tight junctions), which can be considered as equivalent to a combination of 
resistors and capacitors in a circuit [128], though the capacitors are typically neglected 
from the model circuit for simplicity, leaving a series of resistors. Thus, the placement of 
two electrodes opposite each chamber representing the luminal and abluminal 
compartments allows measurement of this resistance.  
According to consensus in the field of in vitro BBB models, a generally accepted 
level of TEER above 150Ωcm2 is characteristic of a good in vitro model [129-131], while 
in vivo microvessels commonly reach 1800 Ωcm2 [132]. In contrast, peripheral TEER in 
vivo is typically measured to be less than 100 Ωcm2. It is worthy of note that TEER results 
are difficult to compare or repeat across separate laboratories [129]. For example, one 
group has published TEER values of 400-700 Ωcm2 [133] with commercial Endohm 
chambers, significantly lower than data measured with custom equipment in the same 
laboratory between 1200-1800 Ωcm2 [134] under the same conditions. Thus, TEER is 
most useful when used as a quality control measure for experimental consistency, as a 







2.5.2 Trans-BBB Permeability Methods 
 The most direct measurement of BBB function of an in vitro model is 
measurement of compound tracers. The relationship between TEER and solute transport 
is not necessarily linear, since transport depends on a combination of transport through 
all paracellular pathways (tight junctions), while TEER depends on areas with lowest 
electrical resistance between cells [135]. Indeed it was shown that at TEER values higher 
than 130 Ωcm2, paracellular permeability was independent of TEER status [136]; 
therefore, paracellular permeability should be monitored with tracer compounds. To be 
used as a marker of paracellular transport, tracer compounds should not be compounds 
which work as ligands for transcellular transporters [129]. There are many convenient, 
fluorescent compounds which fit this category, such as sodium fluorescein [137], lucifer 
yellow [138], propidium iodide, or fluorescein isothiocyanate (FITC)-labeled dextrans 
[139]. FITC-Dextran is particularly convenient, and was used in each of the proposed 
studies, because it comes in many sizes, allowing monitoring of permeability according 
to size difference with physicochemical consistency.  
The flow-based microfluidic permeability assay platform provides diffusive 
conditions much closer to that of in vivo than in large-scale static systems. Because at 
such sub-mm scales, compound transport is dominated by the convective effect [140] due 
to the laminar flow profile in capillaries or microchannels, test compounds provided by 
the steady laminar flow, permeability rates are dependent on the supplied concentration, 





2.5.3 Imaging Methods 
 In addition to barrier function measurement with TEER and permeability, cellular 
function can be monitored using methods of microscopy. Fluorescence microscopy of 
immobilized, fixed cultures of BBB cells allows monitoring of the localized expression 
of specific proteins. One of the most important of these compounds is considered to be 
ZO-1, one of the key components of tight junctions [52]. Expression of this compound is 
essential to barrier function; therefore, an endothelial monolayer lacking clear expression 
of ZO-1 is expected to be lacking in barrier function. Second, the use of microscopy 
allows monitoring of morphological characteristics, such as cell shape and orientation. 
Cellular morphometry is particularly relevant as it relates to the response to shear stress 
[141]. 
 
2.5.4 Protein Expression Techniques 
Direct assays of protein expression is useful for characterizing constituent cells 
used in the model. An analytical technique useful for monitoring the expression of 
specific proteins in a cell population is western blot. Total protein extracts from the 
population of cells are separated by gel electrophoresis according to size or charge, and 
are transferred to a nitrocellulose or polyvinylidene fluoride (PVDF) membrane, where 
they can be stained with specific antibodies [142]. The expression of this antibody is 
proportional to the total protein expressed, and can be quantitated using band 
densitometry. Any compound can be used for this technique, as long as there are 
antibodies available. Also, the expression, hence activity, of P-gp can be directly assayed 





comprehensive BBB functional characterization, because TEER and permeability are 
focused on the paracellular pathway, while assays observing P-gp activity and expression 
focuses on the transcellular pathway, both of which are constituents of BBB function. 
 
2.5.5 Microfluidics Simulations 
 Flow characteristics of the microfluidic structures used in this dissertation were 
elucidated early with the use of computational simulations. These simulations were 
conducted using Comsol 4.0, with the laminar flow multiphysics module. Drafted CAD 
files of the microfluidic structures can be exported into the Comsol model, or drawn 
within the software itself. 3D models with geometric meshes with approximately 3-
5,000,000 element number were used to maximize model precision, while staying within 
the memory limits of the computers used (16 GB RAM). Assumptions made within these 
models include a Newtonian fluid with dynamic viscosity of 1.2 mPa·s (DMEM media 
with 5% fetal bovine serum), and with input conditions of flow-rate at the inlet, with 0 
pressure at the outlets. Comsol’s output is the flow velocity fields and the shear rate at all 
locations along the walls. From the shear rate, shear stress is calculated by multiplying 
the dynamic viscosity. 
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CHARACTERIZATION OF A MICROFLUIDIC IN VITRO MODEL OF 
THE BLOOD-BRAIN BARRIER (µBBB)1 
 
3.1 Abstract 
The blood-brain barrier (BBB), a unique selective barrier for the central nervous 
system (CNS), hinders the passage of most compounds to the CNS, complicating drug 
development. Innovative in vitro models of the BBB can provide useful insights into its 
role in CNS disease progression and drug delivery. Static transwell models lack fluidic 
shear stress, while the conventional dynamic in vitro BBB lacks a thin dual cell layer 
interface. To address both limitations, we developed a microfluidic blood-brain barrier 
(µBBB) which closely mimics the in vivo BBB with a dynamic environment and a 
comparatively thin culture membrane (10µm). To test validity of the fabricated BBB 
model, µBBBs were cultured with b.End3 endothelial cells, both with and without co-
cultured C8-D1A astrocytes, and their key properties were tested with optical imaging, 
trans-endothelial electrical resistance (TEER), and permeability assays. The resultant 
imaging of ZO-1 revealed clearly expressed tight junctions in b.End3 cells, Live/Dead 
assays indicated high cell viability, and astrocytic morphology of C8-D1A cells were 
confirmed by ESEM and GFAP immunostains. By day 3 of endothelial culture, TEER 
1 Reproduced by permission of The Royal Society of Chemistry. Published: Lab on a Chip, 2012, Vol 12, 
p 1784-1792. http://pubs.rsc.org/en/content/articlelanding/2012/lc/c2lc40094d 
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levels typically exceeded 250Ωcm2 in µBBB co-cultures, and 25Ωcm2 for transwell co-
cultures. Instantaneous transient drop in TEER in response to histamine exposure was 
observed in real-time, followed by recovery, implying stability of the fabricated µBBB 
model. Resultant permeability coefficients were comparable to previous BBB models, 
and were significantly increased at higher pH (>10). These results demonstrate that the 




Diseases of the central nervous system (CNS) present a prevalent and ever-
increasing burden for the world healthcare industry. For example, Alzheimer’s disease is 
diagnosed in an estimated 24 million people, a number projected to double every 20 years 
[1]. Despite such emerging demands for treatment of CNS diseases, only 7% of CNS 
drugs in clinical development reach the marketplace (Figure 3.1A), compared to the 12% 
average across all therapeutic areas, or 20% for cardiovascular drugs [2,3]. 
This low success rate is attributed primarily to a unique CNS structure coined as 
the blood-brain barrier (BBB) [3], which introduces a pharmacokinetic hurdle by 
blocking compounds from entering brain tissues from capillaries [4]. Only compounds 
smaller than about 500Da easily cross the BBB, but few CNS diseases consistently 
respond to this category of molecules [5].  
Because the BBB blocks nearly all polar or large compounds, new drug treatments 
for the CNS of higher molecular weight must take BBB function into account, requiring 





Figure 3.1 Motivation and background for µBBB development. (A) Probability 
of success is lower for new CNS drugs than those in other healthcare areas due to the 
unique architecture of brain capillaries [2]. (B) The CNS is unique due to the 
extraordinary selectivity of the BBB [3]. Better model systems of the BBB will contribute 
to development of CNS disease treatments. Effective in vitro BBB models should 
successfully include key properties: (1) endothelial cells with tight junction expression; 
(2) co-culture with astrocytes; (3) presence of shear stress; (4) selective permeability to 
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the conventional pharmaceutical approach focusing on drug design, help predict the 
penetration of drug candidates across the BBB [24], and allow prescreening and 
optimization of new treatments prior to animal and clinical studies [25]. BBB models can 
also be used to study the role of barrier function on CNS disease progression [26], and 
test innovative methods of delivery [27].  
BBB studies have been performed largely in two platforms: in vivo and in vitro 
models (Table 3.1). In vivo models directly utilize entire living organisms, typically rats 
or mice, while in vitro models construct artificial environments with cultured cells to 
mimic in vivo structures. In vitro models are a valuable precursor to animal models due 
to lower cost, time, and ethical constraints. More specific to the BBB, unlike in animal 
studies, in vitro models enable controlled, repeatable, and noninvasive tests: permeability 
assays, resistance measurements, and microscopy. 
 
Table 3.1 Qualitative comparison of standard BBB models with the µBBB 
proposed in this article. 
 
 
Experimental system In vivo 
models 











Relative cost High Very Low Low Low 
Massively-parallel, controlled, and 
repeatedly identical 
No Yes Yes Yes 










Space between co-cultures Immediate <10 µm >150 µm <10 µm 
Functional media volumes N/A 0.5-2 ml 1.4 ml 12 µl 
Time to steady-state TEER N/A 3-4 days 9-12 days 3-4 days 
TEER electrodes – Ion flow profile 
(Gap size) 
(Fixed position) 









Nondestructive microscopy No Yes No Yes 





Although traditional in vivo models provide environments closer to the human 
phenotype, they cannot provide massively-parallel, controlled, and repeatedly identical 
environments for reliable and quantitative studies (Table 3.1). More importantly in terms 
of practicality, in vivo models require extraordinary amounts of cost, time, and man-hours 
per test, while increasingly facing ethical issues as well.  
In vitro models are able to significantly reduce such issues by offering identical 
environments in numerous arrays, as well as lower cost, time, and ethical constraints. 
Thus, the development of valid in vitro models can facilitate the overall drug development 
process by acting as a precursor, or even a replacement, for animal studies. 
The validity of an in vitro model is dependent on how well it reproduces the key 
physiological and biological characteristics of its in vivo archetype (Figure 3.1B). The 
key characteristics of the BBB include: (1) the primary structure, consisting of strongly 
expressed tight junctions between endothelial cells which directly control compound 
permeability [28]; (2) co-culture of endothelial cells with astrocytes including endfoot 
contact, which plays an important role in modulating barrier function through cell-cell 
signaling [29]; (3) mechanotransductive effects of shear stress from fluid flow on 
endothelial cells, which is known to critically influence cell differentiation and tight 
junction formation [30,31]; (4) selective permeability from the constituted structures to 
dissolved compounds; (5) maintenance of high electrical resistance representing the 
maturity and soundness of the structures. 
To mimic such key characteristics, various in vitro models have been developed 
to date [9-22] and can be mainly divided into two groups: static and dynamic models, 





cells. Static models have been the most widely used since the first transwell setup in 1991 
[11]. Recently, dynamic in vitro BBB (DIV-BBB) [20-22] models have been developed 
which utilize hollow fibers to mimic the BBB architecture and flow conditions, providing 
adequate shear stress. However, wall thickness (150µm) is significantly higher than 
transwell thickness (10µm), discouraging cell-cell interaction, and DIV-BBBs take 
significantly longer to reach steady-state TEER values [20,32] than static transwell 
models. To our knowledge, no existing BBB systems have addressed each of these 
shortcomings yet. 
 In order to address the issue, we have developed a microfluidic BBB (µBBB) [23] 
that  includes each of the following advantages over existing in vivo and in vitro static 
and dynamic BBB Models (Table 1): (1) significantly lower costs and timescales than in 
vivo studies; (2) massively-parallel, controlled, and repeated environments not available 
in in vivo models; (3) dynamic microenvironment providing shear stress stimulation to 
the cells, and allowing the improved analysis of test compounds and controlled delivery 
compared to static models; (4) much thinner culture membrane, decreasing the distance 
between co-cultured cells from DIV-BBB  models. In addition, the developed µBBB 
model uses smaller functional volumes for quicker media exchange and material 
conservation. Shorter times to steady-state TEER levels allow a more rapid turn-around 
time, shortening experiments and allowing a more high-throughput approach to 
experimentation. The developed µBBB also enables installation of high-density 
electrodes with tiny (200 µm) gaps between either electrode and the cell layers, with 
uniform ion flow density, minimizing background resistance and error. Nondestructive 





transparency of the substrate. Finally, the developed µBBB is polymer-based, allowing 
comparatively rapid and low-cost fabrication. 
 This paper reports the detailed design, fabrication, and characterization of the 
developed in vitro dynamic thin-membrane µBBB system, including multilayered 
polymer fabrication, cell culturing procedure, validation of the developed models through 
optical imaging, static and transient permeability tests, and TEER measurements under 
different concentrations of various tracers. 
 
3.3 Structure and Fabrication 
3.3.1 Structure 
The developed µBBB is a multilayered microfluidic device comprising four 
PDMS substrates, two glass layers, and a porous polycarbonate membrane sandwiched at 
the center between the PDMS layers (Figure 3.2A). The assembled device houses two 
perpendicularly-crossing channels to introduce dynamic flows, a porous membrane at the 
intersection of the flow channels for cell culture, and multiple embedded electrodes to 
monitor TEER across the barrier. The channels are 200µm high, and 2mm (luminal) or 
5mm (abluminal) wide at the cell culture interface ensuring laminar flows. The porous 
membrane is located at the channel junction has an area of 10mm2 (Figure 3.2B-C). The 
abluminal channel has a high aspect ratio (10:1) to promote uniform shear stress 
distribution across endothelial cells, and the luminal channel is significantly wider to 
minimize shear stresses on the astrocytes. Opposite the membrane on each side are two 
sets of two AgCl thin-film TEER electrode pairs forming a four-point sensing structure. 





Figure 3.2 Structure and design of the developed µBBB. (A) The µBBB system 
comprises two perpendicular flow channels. (B) The fully fabricated µBBB chip. (C) 
Close-up view. Channels model the lumenal (blue) and ablumenal (red) sides of the 
neurovascular unit. Endothelial cells and astrocytes are respectively cultured on the 
lumenal and ablumenal sides of the enclosed porous membrane. Channel heights are 200 




























culture area in order to encourage uniformly distributed ion flow. For interconnection, 
there are two pairs of fluidic and electrical I/Os, respectively. 
 
3.3.2 Fabrication 
The µBBB was fabricated by sequentially bonding the four patterned PDMS sub-
layers, two embedded electrode layers, and the sandwiched polycarbonate membrane, 
resulting in a fully integrated device (Figure 3.3). First, electrode layers were produced 
by cleaning 1mm glass slides with piranha etch, and sputter depositing (Denton Discovery 
18) thin-film electrodes with 20nm Cr, 150nm Au, and 800nm Ag. Instachange marking 
film (3M) was patterned with a laser patterning system (Universal) to be used as a sputter  
 
Figure 3.3 Components of the µBBB. The µBBB consists of four PDMS layers, 





mask. Silver surface was chlorinated chemically with FeCl3 for 60s at room temperature 
to generate an electrochemically active AgCl surface. Glass slides were diced (Disco 
DAD641) to 18mm by 25mm and embedded in 3mm thick PDMS and cured at 65° for 
2h. Four I/O holes (0.5mm) were cored in the top layers by punching.  
 To produce the channel feature layers, PDMS prepolymer was spin-coated at 288 
RPM for 1m and cured at 65°C for 2 hours to produce 200µm sheets, and features were 
laser-patterned. Polycarbonate sheets (400nm pores, 10µm thick) were cut from 
transwells (Corning) to 5x10mm rectangles. The top and bottom PDMS layers, the 
polycarbonate sheets, and the PDMS channel layers were bonded using spin-coated and 
stamped 50:50 ratio PDMS pre-polymer:toluene as previously described [33]. Copper 
wire was bonded to bond-pads with silver epoxy for electrical connections. 
 
3.4 Cell Culture 
In order to form a dual-layer BBB on the chip, co-culture of endothelial and 
astrocytic cells was performed by seeding on both sides of the porous membrane in the 
fabricated device by flowing cell suspensions. Specifically, b.End3 (endothelial) and 
C8D1A (astrocyte) cell lines were employed utilizing standard mammalian tissue culture 
methods for their ease of use. 
The fabricated µBBB platform was sterilized and adhesion-seeded by steadily 
perfusing for up to seven days. Gas-permeable manifold tubing (0.25mm ID) was 
attached to 22½ gauge needles and 10µl pipet tips. Tips were sealed to theinlet holes with 
silicone sealant (DC734), and chips were connected to a 205S peristaltic cartridge pump 





Figure 3.4 Testing setup for validating the µBBB. Fully assembled µBBB 
includes gas-permeable tubing run through a peristaltic pump to a plugged reservoir for 
each channel. Electrode wiring is connected through an electrode adaptor to an EVOM 
Epithelial Voltohmeter for TEER measurement. 
 
reservoirs, covered with gas-permeable TFE/silicone plugs (BioTech Solutions). Chips 
were perfused with 70% ethanol to prevent contamination. To facilitate cell adhesion, the 
membrane was coated with 10µg/ml fibronectin for two hours, then filled with growth 
medium and fully cleared of bubbles prior to cell seeding. 
Next, the platforms were first seeded on the abluminal side with astrocytes at the 
concentration of 6e4/cm2 by flooding concentrated cell suspension (3e6/ml) in the 
abluminal chamber and inverting the devices at zero flow for two hours. Before seeding 





Then, b.End3 [34] cells were secondly seeded at the concentration of 6e4/cm2 in 
the luminal channel and allowed to adhere for two hours before rinsing with medium 
perfused at 1.3µl/min for twelve hours, followed by 2.6µl/min subsequently.  
Note that cells used for seeding BBB models were taken from confluent cultures 
(after D3 after passage) only. Static BBB models were tested by seeding astrocytes at 
6e4/cm2 on the underside of transwells (Corning) pretreated with 10µg/ml human 
fibronectin (Cultrex) in PBS for two hours and allowed to adhere for two hours, then 
cultured for two days prior to endothelial cell seeding on the topside at 6e4/cm2.  
All cell cultivation and BBB experiments, including the devices and pump 
assembly, were carried out in a Nu-Aire Autoflow 4750 incubator which maintains a 
constant interior environment at 5% CO2 and 37°C, as indicated by internal temperature 
and CO2 sensors in the incubator, with certified accuracies of +0.0125°C and +0.1%, 
respectively. Cell suspensions were centrifuged in an Eppendorf 5810, and sterile work 
was done in a class II biosafety cabinet (Thermo Fisher). Media used for all procedures 
was DMEM:F12 (CellGro), supplemented with 10% FBS (Hyclone), 1% 
Penicillin/Streptomycin, and 1% Fungizone (EMD). Media was buffered (NaOh or HCl 
buffers) to 7.4pH (VWR sympHony) and sterile-filtered for all experiments, except for 
experiments in which media was buffered to 10pH. All media was supplemented with 1.2 
g/L sodium bicarbonate to minimize changes in pH, though any changes in pH over the 
course of µBBB experiments were not measured due to volume limitations of the pH 







3.5 Testing Methodology 
To validate the fabricated µBBB system, the three most common methods were 
employed [35]: (1) cell imaging to observe structure and morphology, (2) TEER levels to 
evaluate cell confluence and tight junction integrity, and (3) permeability assays to 
evaluate barrier selectivity. Cells were imaged with a Live/Dead assay to verify cell 
viability, and immunostained to look at expression of astrocyte marker GFAP and tight 
junction component zonal occluding-1 (ZO-1). TEER was measured as an indicator of 
cell confluence and tight junction integrity, with time to maximum TEER being indicative 
of BBB development time. Fluxes of fluorescent-labeled tracer molecules were measured 
to assess permeability to larger solutes. To observe the system’s response to 
environmental changes, cells were exposed to histamine during TEER measurement and 
high pH during permeability assays. Real-time TEER was measured in co-cultured µBBB 
models during exposure to histamine (Calbiochem) at 100 µM and 150 µM 
concentrations. Permeability was measured in µBBB models exposed to DMEM:F12 
media with elevated pH (>10) for four hours. 
 
3.5.1 Imaging 
Light-phase and ESEM imaging were used for morphological observations, 
Live/Dead assay was used to assess viability, and immunostaining was used to look at 
expression of glial and tight junction marker proteins GFAP and ZO-1. To assess viability 
of cultured cells, Live/Dead (MGT) solution was incubated for ninety minutes and 
imaged using a Nikon fluorescence microscope. For immunostaining of both cell types, 





temperature. Cells were permabilized with 0.1% Triton X-100 in PBS for 10m and 
blocked with 5% goat serum (Rockland) and 1% unconjugated goat anti-mouse IgG 
F(ab’)2 fragment (ImmunoPure) in permeabilization buffer for one hour. Cultures were 
incubated with primary antibody in blocking solution overnight at 4ºC. Cultures were 
rinsed with blocking solution and left in secondary antibody for one hour, counter-stained 
with DAPI (Enzo) for five minutes, and imaged with a Nikon fluorescence microscope. 
Mouse anti-ZO-1 (Invitrogen) was used in conjunction with Alexa Fluor 488 goat anti-
mouse secondary antibody (Invitrogen). Rabbit anti-GFAP (Invitrogen) was used in 
conjunction with Alexa Fluor 488 goat anti-rabbitt secondary antibody (Invitrogen). For 
imaging with environmental SEM (FEI Quanta 600 FEG), astrocyte cultures were rinsed 
and fixed in 4% paraformaldehyde solution for twenty-four hours at 4°C. 
 
3.5.2 TEER Measurement 
Over the course of BBB experiments, TEER was measured twice a day to monitor 
cell confluence and development of tight junctions. For measurement of TEER, voltage 
and current electrode wires were connected via an electrode adaptor (WPI) to an EVOM2 
epithelial voltohmeter (WPI). The EVOM2 passes a constant 10µA AC current at 12.5Hz 
while measuring resistance. To calculate TEER, initial D0 Background resistances Rb 
were subtracted from total resistance RC at each time point and normalized for area, 
giving TEER values in Ωcm2 as in the following equation. 
 𝑇𝑇𝑇𝑇𝑇𝑇𝑅𝑅 = (𝑅𝑅𝐶𝐶 − 𝑅𝑅𝑏𝑏)𝐴𝐴 (3.1) 
For real-time data collection during histamine exposure, the EVOM2 was connected to 





cultures were measured daily by placing them in an Endohm chamber (WPI) and 
connecting it to the EVOM2. 
 
3.5.3 Permeability 
To assess barrier permeabilities to large compounds, fluxes of fluorescent tracers 
over a wide range of sizes were measured after steady-state TEER has been reached under 
each variant condition: monolayer, co-culture, and co-culture with elevated pH. The 
permeability of the system to dissolved compounds is detected by measuring the rate of 
diffusion across the membrane. After D3 of endothelial culture, FITC-Dextrans 4k, 20k, 
70k (Sigma), and propidium iodide (Biotium) were passed at a concentration 500µg/ml 
in media through the luminal channel of each device, and blank media was passed through 
the abluminal channel. The level of fluorescence in the media collected from the 
abluminal channels were measured using a BioRad Synergy Plate Reader, and converted 
to concentration according to prepared standards. Solute flux Js was calculated by 
dividing concentration change by assay time. Permeability coefficients were calculated 





where P is the permeability coefficient, Js is solute flux across the membrane, A is 
membrane area, and CL is concentration on the luminal (source) side of the membrane.  
Epithelial coefficients Pe were calculated by subtracting the inverse of the overall P value 
by the inverse of coefficient Pb from a blank membrane, as in the following equation for 













All permeability assays were conducted after day 3 of endothelial culture. Assays were 
conducted for both monolayer and co-cultured devices. To evaluate the effect of pH 
elevation on permeability, assay was repeated with cultures exposed to media containing 
pH>10 for four hours. 
 
3.6 Results and Discussion 
The measurements indicated the validity of the developed µBBB model as an 
effective in vitro model system for studies of barrier function and drug delivery. The 
generally recognized characteristics of a valid in vitro BBB model include practicality 
and ease of use, in vivo-like cell morphology, functional expression of BBB-specific 
proteins, and a restricted paracellular pathway as indicated by high TEER and low 
permeability to compounds [38]. The b.End3 cell line has been previously characterized 
as having acceptably high functionality of P-glycoprotein transporter, as well as 
expression of numerous transporters [34]. Finally, the restrictive paracellular pathway 
was demonstrated by TEER levels over 250 Ωcm2 and tracer permeabilities comparable 
to previous BBB models [37]. 
 
3.6.1 Imaging 
Imaging results were indicative of in vivo-like morphologies for both cell types, 
validating structural requirements for BBB. Results from Live/Dead assays conducted on 





endothelial cells cultured in the system (Figure 3.5A) Similar cell survival was seen for 
astrocytes cultured in the system. Immunostains of b.End3 cells cultured in the system 
revealed distinct expression of tight junction component ZO-1 by day 3 of culture (Figure 
3.5B). Immunostains on D2 typically lacked as clearly distinct expression of ZO-1 as 
seen on day 3-4, suggesting a three-day minimum for full barrier development, consistent 
with the TEER results. Evaluation of the endothelial monolayer structure of b.End3 cells 
confirmed previous analysis on the cell line as valid for BBB models [34], that tight 
junctions were readily expressed by day 3 of culture in the system, even without astrocyte 
co-culture.  
Morphological analysis of the C8-D1A cell line was necessary due to a lack of 
described previous models using the cell line. The C8D1A cell line regularly expressed 
an astrocytic morphology with distinct neurites. Immunostains of C8D1A cells revealed 
expression of GFAP, which is a marker specific to astrocytes (Figure 3.5C). ESEM of 
astrocytes cultured on polycarbonate membrane revealed good adhesion to the substrate 
(Figure 3.5D), though the neurites were typically wider (>1µm) than the pore diameter 
(0.4µm), so it is unlikely that endfeet were able to migrate through the pores. Further 
study should be performed to find a feasible membrane with large enough pores to 
encourage direct cell-cell contact between cell types, while not large enough to introduce 
problems with adhesion or cell migration through the membrane.  
Note that the experimental setup was small enough for the entire pump system to 
be placed in the incubator at 37°C, and up to 4 devices could be run simultaneously with 
our 8-channel pumphead. Imaging indicated that both cell types exhibited characteristics 





































Figure 3.5 Representative images of cells in µBBB. (A) Live/Dead stain 
(green:live, red:dead) of bEnd.3 cells on day 3 of culture on µBBB membrane indicates 
high cell viability. (B) Immunostains of tight junction component ZO-1 (green) in bEnd.3 
cells on day 3 indicate distinct tight junction expression. Nuclei counter-stained with 
DAPI (blue). (C) Immunostains of GFAP (green) in C8-D1A cells reveal astrocytic 
morphology on polycarbonate membrane. Nuclei counter-stained with DAPI (blue). (D) 










TEER results indicated acceptably high [39] electrical resistance for BBB models, 
with conveniently short time to steady-state TEER levels, and effectively demonstrated a 
transient response to histamine. For both static transwell experiments and dynamic µBBB 
cultures, cultures typically reached steady-state levels by day 3-4 of endothelial cell 
culture (Figure 3.6). This is indicative of full tight junction development, in congruence 
with the ZO-1 imaging data, so day 3 was the minimum threshold for endpoint testing 
such as permeability assays, immunostains, and TEER response assays. For both systems, 
co-culturing endothelial cells with astrocytes significantly increased the steady-state 
TEER levels, as indicated by the arithmetic means over several runs shown in Figure 3.6. 
 
 
Figure 3.6 TEER levels of static and dynamic experiments over time, beginning 
on D0 of endothelial culture. (A) TEER development of transwells seeded with b.End3 
cells in monoculture and in co-culture with astrocytes. (B) TEER development of µBBB 
devices seeded with b.End3 cells in monoculture and in co-culture with astrocytes. Both 






3.6.2.1 Steady-State TEER Measurements 
The steady-state TEER values in dynamic µBBB chips were significantly higher 
than our static transwell controls (Figure 3.7) using the same cell lines, media 
formulations, and voltohmeter. TEER levels of µBBB co-cultures regularly exceeded 
250Ωcm2, compared to only 25Ωcm2 in transwell co-cultures. Supported by previous 
studies reporting shear stress effects on endothelial cells [31,40-48] we reasonably 
hypothesize that this significant increase in TEER may be due to the effects of shear stress 
on endothelial cells. Shear stress has a known mechano-transductive effect on endothelial 
molecular pathways [44,45,48], and has been seen to up-regulate expression of tight 






Figure 3.7 Steady-state TEER levels of each base condition. Dynamic cultures 
reached significantly higher TEER levels than static cultures. For both systems, co-





vascular endothelial cells, modulate cytoskeletal structure [31,42], and shows less 
inflammatory effects with definitive directional flow [46] than disturbed flow [49]. 
However, other differences exist between the µBBB system and our transwell 
controls which may factor into differences in results, such as total cell numbers and media 
volumes, culture surface/volume ratios, ratio between endothelial cells and astroctyes, 
and TEER electrode characteristics such as size, gap, and orientation. 
Though in vivo TEER levels are greater than 1000 Ωcm2, a consensus has been 
reached that for a system showing sufficiently high TEER levels over 150 Ωcm2, 
reasonably representative data can be obtained [39], while our system typically exceeded 
250 Ωcm2. 
 
3.6.2.2 Dynamic TEER Measurements 
A transient drop and recovery to the original levels in TEER was observed as a 
result of exposure to histamine (Figure 3.8), indicating the robustness of the model for 
repeated at long-term testing purposes. The drop occurred very rapidly upon exposure to 
histamine, and TEER returned to initial levels within six minutes at 100µM histamine 
concentration, and fifteen minutes for 150µM concentrations. Maximum TEER drop was 
approximately 30% for 100µM histamine, and 50% for 150µM histamine. A similar 
transient response of endothelial cells to histamine has been reported in previous studies 
[50-54]. This effect has been attributed to brief formation of trans-endothelial gap 
formation [55], and has also been suggested to be due to increased trans-cytosis [56]. The 
ability to observe real-time transient changes in TEER without disturbing the system is a 





Figure 3.8 Continuous response to histamine exposure in three samples at each 
concentration. Co-cultured µBBB on D4 were perfused with histamine at two 
concentrations. (A) Three samples perfused with 100µM histamine saw a transient drop 
of up to 30% over a period of five-seven minutes. (B) Three samples perfused with 
150µM histamine saw a transient drop of up to 50% over a period of eight-fifteen minutes. 
 
3.6.3 Permeability 
Permeabilities of µBBB cultures to large molecules were shown to be selective 
according to size, and seen to be slightly lower for co-cultures than endothelial cells alone, 
and found to be higher when pH is significantly elevated. The µBBB system is 
advantageous for permeability assays, because Equation 3.2 assumes tracer 
concentrations are kept constant, which is not necessarily true for static models in which 
concentrations in both chambers change with time. This is a valid assumption for flow-
based BBB models, because fresh media at constant concentration is continuously 
delivered to the chamber. Permeability coefficients of Dextrans 4kD, 20kD, and 70kD, 
and propidium iodide were calculated and plotted according to stokes radius, or the radius 
of a sphere with the same diffusive properties (Figure 3.9). Results for all conditions 





Figure 3.9 Permeabilities of cultured µBBB under different conditions. Tracer 
molecules FITC-Dextrans 4k, 20k, 70k, and propidium idodide reveal selectivity 
according to size. Also plotted for reference is in vivo data from a previous study[7], 
which showed a lower permeability curve than all in vitro models. Co-cultures showed 
lower permeability than monocultured b.End3 cells alone. Increasing pH to 10 for four 
hours resulted in significantly increased permeabilities. All n>3. 
 
compounds pass through junctions easier. Co-cultured systems showed lower 
permeability than for monoculture of endothelial cells alone, consistent with the higher 
TEER levels. Exposing µBBB co-cultures to significantly higher pH levels (>10) for four 
hours led to significantly higher permeabilities to all tracers, indicating loss of barrier 
function. This increase in permeability due to heightened pH has been observed in 
previous BBB models [57,58], and is indicative of a drop in barrier function. However, 
permeabilities for both co-cultures and endothelial monoculture were higher than those 
previously reported from in vivo studies [7]. To our knowledge, results from a BBB model 






We have developed a µBBB that effectively mimics the dynamic cerebrovascular 
environment with fluid shear stress, and the results from this characterization study 
indicate that the model expresses sufficient key characteristics of a BBB model. Tight 
junction expression in the b.End3 cells and GFAP expression were characteristic of in 
vivo. The µBBB showed significantly higher TEER levels than in static models, with a 
comparatively short time to steady-state TEER to the DIV-BBB system. Real-time TEER 
response was shown to be feasible through measurement of transient effects histamine 
testing. Permeability assays were demonstrated in the system, with a selective 
permeability over a wide range of tracer sizes. These characteristics indicate that the 
µBBB system is a useful and enabling tool for further studies of BBB function and 
delivery. It can be used to monitor changes in barrier function in response to various 
environmental stimuli, such as barrier-enhancing or barrier-opening drugs. Finally, 
through permeability assays the system can be used to predict the rate of delivery of new 




This research was supported by the Utah Science Technology and Research 
Initiative (USTAR) and the DARPA Young Faculty Award 2011 (N66001-11-14149). 
Microfabrication was performed at the state-of-the-art University of Utah Nano 







[1] Ferri, C. P., M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, M. Ganguli, K. 
Hall, K. Hasegawa, H. Hendrie, and Y. Huang. Global prevalence of dementia: 
A delphi consensus study. The Lancet. 366(9503):2112-2117, 2006. 
[2] Pangalos, M. N., L. E. Schechter, and O. Hurko. Drug development for cns 
disorders: Strategies for balancing risk and reducing attrition. Nat Rev Drug 
Discov. 6(7):521-532, 2007. 
[3] Pardridge, W. M., W. H. Oldendorf, P. Cancilla, and H. J. Frank. Blood-brain 
barrier: Interface between internal medicine and the brain. Ann Intern Med. 
105(1):82-95, 1986. 
[4] Cardoso, F. L., D. Brites, and M. A. Brito. Looking at the blood-brain barrier: 
Molecular anatomy and possible investigation approaches. Brain Res Rev. 
64(2):328-363, 2010. 
[5] Pardridge, W. M. Blood-brain barrier drug targeting: The future of brain drug 
development. Mol Interv. 3(2):90-105, 151, 2003. 
[6] Soni, S., A. K. Babbar, R. K. Sharma, and A. Maitra. Delivery of hydrophobised 
5-fluorouracil derivative to brain tissue through intravenous route using surface 
modified nanogels. J Drug Target. 14(2):87-95, 2006. 
[7] Yuan, W., Y. Lv, M. Zeng, and B. M. Fu. Non-invasive measurement of solute 
permeability in cerebral microvessels of the rat. Microvasc Res. 77(2):166-173, 
2009. 
[8] Preston, E., J. Slinn, I. Vinokourov, and D. Stanimirovic. Graded reversible 
opening of the rat blood-brain barrier by intracarotid infusion of sodium caprate. 
J Neurosci Methods. 168(2):443-449, 2008. 
[9] Weidenfeller, C., C. N. Svendsen, and E. V. Shusta. Differentiating embryonic 
neural progenitor cells induce blood-brain barrier properties. J Neurochem. 
101(2):555-565, 2007. 
[10] Nakagawa, S., M. A. Deli, H. Kawaguchi, T. Shimizudani, T. Shimono, A. 
Kittel, K. Tanaka, and M. Niwa. A new blood-brain barrier model using primary 
rat brain endothelial cells, pericytes and astrocytes. Neurochem Int. 54(3-4):253-
263, 2009. 
[11] Rubin, L. L., D. E. Hall, S. Porter, K. Barbu, C. Cannon, H. C. Horner, M. 
Janatpour, C. W. Liaw, K. Manning, J. Morales, and et al. A cell culture model 
of the blood-brain barrier. J Cell Biol. 115(6):1725-1735, 1991. 





plexus epithelial cells is modulated by camp-dependent pathways in vitro. Brain 
Res. 853(1):115-124, 2000. 
[13] Raub, T. J. Signal transduction and glial cell modulation of cultured brain 
microvessel endothelial cell tight junctions. Am J Physiol. 271(2 Pt 1):C495-
503, 1996. 
[14] Bruckener, K. E., A. el Baya, H. J. Galla, and M. A. Schmidt. Permeabilization 
in a cerebral endothelial barrier model by pertussis toxin involves the pkc 
effector pathway and is abolished by elevated levels of camp. J Cell Sci. 116(Pt 
9):1837-1846, 2003. 
[15] Neuhaus, W., V. E. Plattner, M. Wirth, B. Germann, B. Lachmann, F. Gabor, 
and C. R. Noe. Validation of in vitro cell culture models of the blood-brain 
barrier: Tightness characterization of two promising cell lines. J Pharm Sci. 
97(12):5158-5175, 2008. 
[16] Schiera, G., S. Sala, A. Gallo, M. P. Raffa, G. L. Pitarresi, G. Savettieri, and I. 
Di Liegro. Permeability properties of a three-cell type in vitro model of blood-
brain barrier. J Cell Mol Med. 9(2):373-379, 2005. 
[17] Cohen-Kashi Malina, K., I. Cooper, and V. I. Teichberg. Closing the gap 
between the in-vivo and in-vitro blood-brain barrier tightness. Brain Res. 
1284(12-21, 2009. 
[18] Li, G., M. J. Simon, L. M. Cancel, Z. D. Shi, X. Ji, J. M. Tarbell, B. Morrison, 
3rd, and B. M. Fu. Permeability of endothelial and astrocyte cocultures: In vitro 
blood-brain barrier models for drug delivery studies. Ann Biomed Eng. 2010. 
[19] Cucullo, L., P. O. Couraud, B. Weksler, I. A. Romero, M. Hossain, E. Rapp, and 
D. Janigro. Immortalized human brain endothelial cells and flow-based vascular 
modeling: A marriage of convenience for rational neurovascular studies. J 
Cereb Blood Flow Metab. 28(2):312-328, 2008. 
[20] Santaguida, S., D. Janigro, M. Hossain, E. Oby, E. Rapp, and L. Cucullo. Side 
by side comparison between dynamic versus static models of blood-brain barrier 
in vitro: A permeability study. Brain Res. 1109(1):1-13, 2006. 
[21] Cucullo, L., M. S. McAllister, K. Kight, L. Krizanac-Bengez, M. Marroni, M. R. 
Mayberg, K. A. Stanness, and D. Janigro. A new dynamic in vitro model for the 
multidimensional study of astrocyte-endothelial cell interactions at the blood-
brain barrier. Brain Res. 951(2):243-254, 2002. 
[22] Neuhaus, W., R. Lauer, S. Oelzant, U. P. Fringeli, G. F. Ecker, and C. R. Noe. A 
novel flow based hollow-fiber blood-brain barrier in vitro model with 





[23] Booth, R. and H. Kim. A multi-layered microfluidic device for in vitro blood-
brain barrier permeability studies. International Conference on Miniaturized 
Systems for Chemistry and Life Sciences. 15(1388-1390, 2011. 
[24] Reichel, A. Addressing central nervous system (cns) penetration in drug 
discovery: Basics and implications of the evolving new concept. Chem 
Biodivers. 6(11):2030-2049, 2009. 
[25] Cucullo, L., B. Aumayr, E. Rapp, and D. Janigro. Drug delivery and in vitro 
models of the blood-brain barrier. Curr Opin Drug Discov Devel. 8(1):89-99, 
2005. 
[26] Hawkins, B. T. and T. P. Davis. The blood-brain barrier/neurovascular unit in 
health and disease. Pharmacol Rev. 57(2):173-185, 2005. 
[27] Pathan, S. A., Z. Iqbal, S. M. Zaidi, S. Talegaonkar, D. Vohra, G. K. Jain, A. 
Azeem, N. Jain, J. R. Lalani, R. K. Khar, and F. J. Ahmad. Cns drug delivery 
systems: Novel approaches. Recent Pat Drug Deliv Formul. 3(1):71-89, 2009. 
[28] Wolburg, H. and A. Lippoldt. Tight junctions of the blood-brain barrier: 
Development, composition and regulation. Vascul Pharmacol. 38(6):323-337, 
2002. 
[29] Haseloff, R. F., I. E. Blasig, H. C. Bauer, and H. Bauer. In search of the 
astrocytic factor(s) modulating blood-brain barrier functions in brain capillary 
endothelial cells in vitro. Cell Mol Neurobiol. 25(1):25-39, 2005. 
[30] Cucullo, L., M. Hossain, V. Puvenna, N. Marchi, and D. Janigro. The role of 
shear stress in blood-brain barrier endothelial physiology. BMC Neurosci. 12(40, 
2011. 
[31] Galbraith, C. G., R. Skalak, and S. Chien. Shear stress induces spatial 
reorganization of the endothelial cell cytoskeleton. Cell Motil Cytoskeleton. 
40(4):317-330, 1998. 
[32] Frampton, J. P., M. L. Shuler, W. Shain, and M. R. Hynd. Biomedical 
technologies for in vitro screening and controlled delivery of neuroactive 
compounds. Cent Nerv Syst Agents Med Chem. 8(3):203-219, 2008. 
[33] Chueh, B. H., D. Huh, C. R. Kyrtsos, T. Houssin, N. Futai, and S. Takayama. 
Leakage-free bonding of porous membranes into layered microfluidic array 
systems. Anal Chem. 79(9):3504-3508, 2007. 
[34] Omidi, Y., L. Campbell, J. Barar, D. Connell, S. Akhtar, and M. Gumbleton. 
Evaluation of the immortalised mouse brain capillary endothelial cell line, 
b.End3, as an in vitro blood-brain barrier model for drug uptake and transport 





[35] Deli, M. A., C. S. Abraham, Y. Kataoka, and M. Niwa. Permeability studies on 
in vitro blood-brain barrier models: Physiology, pathology, and pharmacology. 
Cell Mol Neurobiol. 25(1):59-127, 2005. 
[36] Pardridge, W. M., D. Triguero, J. Yang, and P. A. Cancilla. Comparison of in 
vitro and in vivo models of drug transcytosis through the blood-brain barrier. J 
Pharmacol Exp Ther. 253(2):884-891, 1990. 
[37] Li, G., M. J. Simon, L. M. Cancel, Z. D. Shi, X. Ji, J. M. Tarbell, B. Morrison, 
3rd, and B. M. Fu. Permeability of endothelial and astrocyte cocultures: In vitro 
blood-brain barrier models for drug delivery studies. Ann Biomed Eng. 
38(8):2499-2511, 2010. 
[38] Nicolazzo, J. A., S. A. Charman, and W. N. Charman. Methods to assess drug 
permeability across the blood-brain barrier. J Pharm Pharmacol. 58(3):281-293, 
2006. 
[39] Vastag, M. and G. M. Keseru. Current in vitro and in silico models of blood-
brain barrier penetration: A practical view. Curr Opin Drug Discov Devel. 
12(1):115-124, 2009. 
[40] Thoumine, O., R. M. Nerem, and P. R. Girard. Oscillatory shear stress and 
hydrostatic pressure modulate cell-matrix attachment proteins in cultured 
endothelial cells. In Vitro Cell Dev Biol Anim. 31(1):45-54, 1995. 
[41] Nerem, R. M., R. W. Alexander, D. C. Chappell, R. M. Medford, S. E. Varner, 
and W. R. Taylor. The study of the influence of flow on vascular endothelial 
biology. Am J Med Sci. 316(3):169-175, 1998. 
[42] Ookawa, K., M. Sato, and N. Ohshima. Time course changes in cytoskeletal 
structures of cultured endothelial cells exposed to shear stress. Front Med Biol 
Eng. 5(2):121-125, 1993. 
[43] Desai, S. Y., M. Marroni, L. Cucullo, L. Krizanac-Bengez, M. R. Mayberg, M. 
T. Hossain, G. G. Grant, and D. Janigro. Mechanisms of endothelial survival 
under shear stress. Endothelium. 9(2):89-102, 2002. 
[44] Tzima, E., M. Irani-Tehrani, W. B. Kiosses, E. Dejana, D. A. Schultz, B. 
Engelhardt, G. Cao, H. DeLisser, and M. A. Schwartz. A mechanosensory 
complex that mediates the endothelial cell response to fluid shear stress. Nature. 
437(7057):426-431, 2005. 
[45] Li, Y. S., J. H. Haga, and S. Chien. Molecular basis of the effects of shear stress 
on vascular endothelial cells. J Biomech. 38(10):1949-1971, 2005. 
[46] Chien, S. Molecular basis of rheological modulation of endothelial functions: 





[47] Siddharthan, V., Y. V. Kim, S. Liu, and K. S. Kim. Human astrocytes/astrocyte-
conditioned medium and shear stress enhance the barrier properties of human 
brain microvascular endothelial cells. Brain Res. 1147(39-50, 2007. 
[48] Chien, S. Mechanotransduction and endothelial cell homeostasis: The wisdom 
of the cell. Am J Physiol Heart Circ Physiol. 292(3):H1209-1224, 2007. 
[49] Chien, S. Effects of disturbed flow on endothelial cells. Ann Biomed Eng. 
36(4):554-562, 2008. 
[50] van Nieuw Amerongen, G. P., R. Draijer, M. A. Vermeer, and V. W. van 
Hinsbergh. Transient and prolonged increase in endothelial permeability 
induced by histamine and thrombin: Role of protein kinases, calcium, and rhoa. 
Circ Res. 83(11):1115-1123, 1998. 
[51] Schilling, L. and M. Wahl. Opening of the blood-brain barrier during cortical 
superfusion with histamine. Brain Res. 653(1-2):289-296, 1994. 
[52] Gulati, A., K. N. Dhawan, R. Shukla, R. C. Srimal, and B. N. Dhawan. Evidence 
for the involvement of histamine in the regulation of blood-brain barrier 
permeability. Pharmacol Res Commun. 17(4):395-404, 1985. 
[53] Takeda, T., Y. Yamashita, S. Shimazaki, and Y. Mitsui. Histamine decreases the 
permeability of an endothelial cell monolayer by stimulating cyclic amp 
production through the h2-receptor. J Cell Sci. 101 ( Pt 4)(745-750, 1992. 
[54] Abbott, N. J. Inflammatory mediators and modulation of blood-brain barrier 
permeability. Cell Mol Neurobiol. 20(2):131-147, 2000. 
[55] Wu, N. Z. and A. L. Baldwin. Transient venular permeability increase and 
endothelial gap formation induced by histamine. Am J Physiol. 262(4 Pt 
2):H1238-1247, 1992. 
[56] Deli, M. A., M. P. Dehouck, R. Cecchelli, C. S. Abraham, and F. Joo. Histamine 
induces a selective albumin permeation through the blood-brain barrier in vitro. 
Inflamm Res. 44 Suppl 1(S56-57, 1995. 
[57] Nielsen, H. M. and M. R. Rassing. Nicotine permeability across the buccal tr146 
cell culture model and porcine buccal mucosa in vitro: Effect of ph and 
concentration. Eur J Pharm Sci. 16(3):151-157, 2002. 
[58] Nielsen, H. M. and M. R. Rassing. Tr146 cells grown on filters as a model of 
human buccal epithelium: Iii. Permeability enhancement by different ph values, 










A MULTIPLE-CHANNEL, MULTIPLE-ASSAY PLATFORM FOR 
CHARACTERIZATION OF FULL-RANGE SHEAR STRESS  
EFFECTS ON VASCULAR ENDOTHELIAL CELLS2 
 
4.1 Abstract 
Vascular endothelial cells (VECs), which line blood vessels and are key to 
understanding pathologies and treatments of various diseases, experience highly variable 
wall shear stress (WSS) in vivo (1-60dyn/cm2), imposing numerous effects on 
physiological and morphological functions. Previous flow-based systems for studying 
these effects have been limited in range, and comprehensive information on VEC 
functions at the full spectrum of WSS has not been available yet. To allow rapid 
characterization of WSS effects, we developed the first multiple channel microfluidic 
platform that enables a wide range (~x15) of homogeneous WSS conditions while 
simultaneously allowing trans-monolayer assays, such as permeability and trans-
endothelial electrical resistance (TEER), as well as cell morphometry and protein 
expression. Flow velocity/WSS distributions between channels were predicted with 
COMSOL simulation and verified by measurement with an integrated micro-flow sensor 
array. Biomechanical responses of the brain microvascular endothelial cell line bEnd.3 to 
2 Reproduced by permission of The Royal Society of Chemistry. Published: Lab on a Chip, 2014, Vol 14, 
p 1880-1890. http://pubs.rsc.org/en/Content/ArticleLanding/2014/LC/c3lc51304a 
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the full natural spectrum of WSS were investigated with the platform. Under increasing 
WSS conditions ranging from 0-86 dyn/cm2, (1) permeabilities of FITC-conjugated 
dextran and propidium iodide decreased respectively at rates of 4.06e-8 and 6.04e-8cm/s 
per dyn/cm2; (2) TEER increased at a rate of 0.8 Ωcm2 per dyn/cm2; (3) cells increased 
alignment along the flow direction under increasing WSS; and finally (4) increased 
protein expression of both tight junction component ZO-1 (~5x) and efflux transporter P-
gp (~6x) were observed at 86 dyn/cm2 compared to static controls via western blot. We 
conclude that the presented microfluidic platform is a valid approach for comprehensively 
assaying cell responses to fluidic WSS. 
 
4.2 Introduction 
Vascular endothelial cells (VECs), which line all blood vessels and comprise the 
interface between blood and surrounding tissue, are a key to understanding pathologies 
and treatments of vascular systems, dictating numerous vascular functions critical to 
homeostasis and drug delivery thoughout the body [1,2]. Their governing functions [3] 
include permeability [4], angiogenesis [5], cell migration, proliferation, and apoptosis [6], 
impacting processes involved in inflammation [7], thrombosis [8], metastasis [9], and 
drug pharmacokinetics, all of which play critical roles in pathology and treatment of the 
two leading causes of death in the US [10]: cancer [11] and cardiovascular disease [12], 
as an example.  
VECs have been found to delicately regulate such functions in response to 
dynamic microenvironments, and one major environmental parameter is the shear stress 





through the vasculature. VECs are reported to experience mechontransductive effects 
on cell phenotype when exposed to WSS via membrane-bound mechanosensors [13-15] 
(Figure 4.1A). Such effects include the induced modulation of a myriad of biomolecular 
pathways leading to various physiological responses [16], such as resistance to apoptosis 
[17,18], upregulation of tight junction proteins (ZO-1, occludin) [19], extracellular matrix 
components (fibronectin, laminin) [20], membrane-bound efflux transporters (P-gp) [21] 
and integrins [22], as well as cytoskeletal restructuring and cell reorientation in relation 
to the flow direction [23-28]. The effects caused by WSS impact VEC functions relevant 
to pathology. For example, atherosclerosis, the leading cause of heart attack and stroke 
[29], has been correlated with low stress regions [30], while atheroprotective responses 
have been observed in high-stress regions [31], and WSS as high as 300 dyn/cm2 has been 
measured in cases of vessel stenosis [32]. This variability in cell microenvironment 
indicates the need for comprehensive understanding of the adaptive responses of VECs 
to the WSS applied by the highly dynamic, highly variable microenvironment of the in 
vivo vasculature, and for delineating the practical limitations of dynamic in vitro culture 
conditions.  
The study of VECs’ responses to WSS has remained quite challenging both in 
vivo and in vitro, due to the difficulty in realizing the wide range of WSS conditions (1-
60dyn/cm2) [33] in vivo, and utilizing it for comprehensive assays. Such a large WSS 
range is mainly caused by significant variations of vessel sizes (8µm-2.5cm) and their 
differently localized pressure [34] (Figure 4.1B). In vivo investigation does not provide 
reproducible and controllable testing conditions due to natural variations in tissue 





 Figure 4.1 Studying the relationship between vascular wall shear stress (WSS) 
and endothelial cell (EC) physiology. (A) VECs respond through mechano-transduction 
via mechanosensors (integrins and kinases), ultimately leading to significant changes in 
protein expression, such as in membrane transport, tight junctions, and cytoskeletal re-
organization. (B) The WSS experienced by vascular endothelial cells varies significantly 
(1-60 dyn/cm2) at different geometric locations in vivo. (C) An optimal, fully 
comprehensive approach to testing the relationship between WSS and VEC responses 
requires multiple well-defined, discrete WSS, and extraction of data via multiple assays, 
including trans-membrane testing, per replicate chip. 
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and repeatability of flow conditions [35], have failed thus far to effectively provide 
characterization spanning the physiologically relevant full spectrum of WSS. This is 
because all previous VEC cultures systems for assaying WSS effects (Table 4.1) are either 
limited to a single WSS condition per unit [13,23,26,27,36-45], or are limited in the types 
of feasible assays, due either to a lack of an integrated membrane [46] (preventing assays 
of barrier properties), or to non-uniformity in applied WSS among a cell population under 
assay [47-52] (preventing reliable correlation of assay results with discrete WSS). 
Though recently a closed-loop braille-display device has applied distinctly different WSS 
to three parallel channels [24], it covered only a limited shear stress range of <12dyn/cm2 
due to the limited flow rates from the integrated micro pumps and did not allow trans-
monolayer assay. In summary, no VEC culture system has simultaneously achieved (1) 
multiple on-chip WSS conditions for isolated cell populations, while (2) allowing trans-
membrane assays yet.  
To address such issues, we have developed a multichannel and multiassay 
platform (Figure 4.1C) where a single fluidic input produces multiple distinct WSS 
magnitudes homogenously applied to isolated VEC populations cultured on membranes, 
allowing multiple types of assays in a reproducible and controllable manner. To allow 
rapid characterization spanning the full in vivo WSS range (1-60dyn/cm2), the platform 
employed four parallel channels producing distinct WSS with ~15x range of magnitude. 
In practice, by compounding the on-chip WSS variance with varying input flow-rates, 
useful quantitative data spanning the full spectrum of WSS can be efficiently gathered 
from a single experimental pump setup (16-channel peristaltic pump), and seeded from a 





Table 4.1 Comparison of flow-based in vitro systems for characterizing WSS 
effects on vascular endothelial cells. 
 
 
standard 16-cartridge pump, useful quantitative data spanning the full spectrum of WSS 
can be efficiently gathered from a single experimental pump setup, and seeded from a 
single standard plate (75cm2) compounded by varying input flow rates to each chip, will 
result in 32 distinct WSS. Furthermore, the designed ~15x magnitude range allows a 
single test to cover the full span of WSS experienced in brain capillaries (3-20dyn/cm2) 
[53], which is the origin of the cell line used in this characterization study. Thus, the 
presented approach massively reduces required cells/reagents and turn-around time, 
while allowing unprecedented high-throughput, comprehensive WSS characterization 
assays. To allow trans-membrane assays, including trans-endothelial electrical resistance 
(TEER) and permeability, this platform employs the cross-junction structure used in our  
Dynamic in vitro platforms for characterization of wall shear stress  











Presented microfluidic system Yes Yes Yes 
Microfluidic  
(braille closed-loop) [24]  Yes Yes No 
Rotational systems 
[47-49] 
Yes No Yes 
Microfluidic 
(geometric variation)  
[50-52]  
Yes No No 
Hollow fiber / capillary systems [21,49] No Yes Yes 
Microfluidic  
(constant-width channels)  
[26,36-41]  
No Yes Yes 
Parallel-plate flow chambers 
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Figure 4.2 The presented parallel channel array allows multiple high-throughput 
characterization assays of WSS effects on cultured endothelial cells. Four channels 
subject independent populations of endothelial cells to homogeneous WSS level at a ~15x 
range. Thus, from a single culture plate source with 8 chips in parallel in a single 
peristaltic pump setup, 32 quantitative shear stress assay datapoints can be achieved per 
experiment, spanning the full physiological WSS range (1-60dyn/cm2) with replicates. 
 
previously reported microfluidic BBB model [41]. 
This paper reports the design, fabrication, and testing results of the developed 
multichannel, multiassay WSS platform. To evaluate the effectiveness of the platform to 
produce a wide range of WSS, quantitative testing results are discussed, including 
velocity discretization into parallel channels (1) by COMSOL simulation and (2) by 
experimental measurements with an integrated micro-flow sensor array. Next, the validity 
of the platform as a high-throughput tool to correlate full-spectrum WSS effects with 
VEC properties of a particular cell line was quantitatively verified on the brain 
Parallel chips in 
multi-cartridge 
pump setup (8x)
4x shear stress 
values/chip
Parallel array structure Single source 
of cells (T-75)
From one experiment, 32 
distinct WSS possible 







microvascular endothelial cell line bEnd.3 by measuring (3) cell morphology (cell 
elongation and orientation), (4) trans-monolayer permeability, (5) monolayer TEER, and 
(6) protein expression of tight junctions (ZO-1) and membrane-bound efflux transporters 
(P-gp). 
 
4.3 Structures and Fabrication 
To produce high-variance WSS distributions, a parallel array microfluidic 
structure of four channels was fabricated utilizing standard PDMS processing techniques 
to have significant differences in fluidic resistance among the channels, causing 
variations in the flow velocities and thus the resultant WSS.  
 
4.3.1 Microfluidic Parallel-Channel Structure 
The parallel array platform consists of four top (luminal) channels and one bottom 
(abluminal) channel that cross perpendicularly, all of which were constructed from 
multiple stacked poly-dimethylsiloxane (PDMS) layers (Figure 4.3A). The four luminal 
channels branch from one common inlet and have independent outlets to simplify fluidic 
control and enable high-throughput parallel permeability assays. The four luminal 
channels have discrete widths (0.73, 1.53, 2.33, 3.13 mm) with varying geometries at the 
branching region, subsequently causing different fluidic resistances, flow velocities and 
uniform WSS in each channel. When these channels were constructed in multiple layers 
by stacking PDMS substrates, a porous polycarbonate (PC) membrane was inserted to be 





Figure 4.3 Multichannel device structure and fabrication. (A) Multichannel 
structure comprises 4 channels branched from a common inlet, exerting homogenous 
WSS at 4 distinct values to VECs cultured in the channel. A 2mm channel is fixed below, 
with a free-standing porous polycarbonate membrane as the culture surface. (B) To 
fabricate the multilayered microfluidic devices, sputter-deposited glass electrode layers 
were embedded in PDMS pre-polymer (10:1) over a lithographically defined SU-8 mold 
and cured at 110°C. Channel layers and an APTES-treated polycarbonate membrane were 
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trans-monolayer assays (permeability/TEER) at each junction, as in the previously 
described µBBB system [41]. Flanking both sides of each PC culture surface, a set of 
thin-film AgCL electrodes were located to monitor TEER in the standard four-point 
sensing configuration minimizing error from parasitic resistance from external wires and 
contacts. The channel heights were initially set at 200µm, ensuring laminar flow and 
maxim izing aspect ratio of the channels for WSS uniformity. 
 The platform structure was fabricated (Figure 4.3B) similarly to the previously 
described µBBB system [41] with some modifications. First, embedded electrodes for 
TEER measurement were fabricated on a glass wafer by sputtering Cr/Au/Ag 
(20/80/800nm) and patterning layers using liftoff lithography (LOR-10B photoresist). 
The silver (Ag) surface was chlorinated with 30mM FeCl3 for 50s to convert it into AgCl 
for corrosion resistant electrodes. Next, the channels were constructed among multiple 
PDMS layers. Channel molds were lithographically constructed from SU-8 2075 (200µm 
thick) on a silicon substrate, and silanized overnight with tridecafluoro-1,1,2,2-
tetrahydrooctyl trichlorosilane in a vacuum chamber to minimize stiction and ease the 
separation during the molding process. On top of the SU-8 mold, PDMS layers were 
sequentially cast (10:1 elastomer:curing agent) and heat-cured (110ºC, 30m). Following 
thirty minutes pretreatment of the PC membrane with 5% 3-aminopropyltriethoxysilane 
(APTES) at 80°C [54], a reliable bond between the membrane and PDMS channel layers 
was generated with O2 plasma (125W, 20s) at 25°C. Residual APTES on the membrane 
was dissolved in ethanol. This bond method significantly decreased occurrences of leaks 
under high flow compared with the standard method using spin-coated PDMS pre-





protein required for western blot (>25 µg), a large 5mm-wide, 175mm-long microfluidic 
channel was separately constructed. 
 
4.3.2 Integrated Micro-Flow Sensor Array 
In order to directly measure the WSS distributions in each microchannel and 
confirm the simulation results, a micro-flow sensor array was fabricated and integrated 
into the channel (Figure 4.4A). The flow sensor utilized a standard suspended thermal 
conductivity detector (TCD) configuration [56]. An identical free-standing flow sensor 
was suspended in each channel at 70µm above the bottom wall. Each flow sensor consists 
of a meander-shaped 10µm wide electrode suspended over an area of 1160µm by 490µm 
above a channel. The interval between adjacent electrode crossings was 120µm, while 
the total length of the meander sensor was 7.8mm.  
The micro-flow sensor was fabricated with standard microfabrication techniques 
(Figure 4.4B). First, LPCVD (1µm) silicon nitride was deposited on a Si substrate, 
followed by sputter deposition of Pt/Ti layers (200nm/10nm), which was patterned to 
form 10µm wide sensor signal feed-through lines to the electrical pads. The Pt/Ti layer 
was then electrically passivated by another layer of patterned PECVD silicon nitride 
(450nm). Then the passivation layer was etched by RIE defining the sensor structure. 
Utilizing the same mask, anisotropic DRIE and isotropic Xactive XeF2 etching were 
combined to etch the silicon substrate and partially suspend (with columns) the sensor 
structure at 70µm from the channel surface. Finally, the fabricated substrate was bonded 





Figure 4.4 Micro-flow sensor array structure and fabrication. (A) Fabricated 
micro-flow sensor array to measure WSS distributions in the parallel array structure. The 
micro-flow sensor structure is the same for all four channels, except the connecting bridge 
structure. (B) Fabrication process for the integrated micro-flow sensor in each 
microchannel. The sensor was fabricated on a N-doped silicon substrate by depositing 
LPCVD nitride, lift-off patterning 10µm wide Pt/Ti electrodes, depositing PECVD 
nitride, then layer and bulk etching the sensor structure with RIE, DRIE, and Xactix to 












4.4 Cell Culture 
The cell line tested in this study was the brain endothelial cell line bEnd.3 [57]. 
The cells were grown with DMEM/F12 (Lonza), and was supplemented with 10% fetal 
bovine serum (Hyclone), 1% Penicillin/Streptomycin and amphotericin B (EMD). Media 
pH was buffered to ~7.35 for all experiments. All cells used for experiments were taken 
from confluent cultures only, within two days after confluence was reached. All cell 
cultivation and shear stress experiments were carried out in a humid incubator (Nu-Aire 
Autoflow 4750) with 5% CO2 kept at a constant 37°C. Cell suspensions were centrifuged 
in an Eppendorf 5810, and all sterile work was performed in a class II biosafety cabinet 
(Thermo Fisher). Sterilization of microfluidic devices and tubing was carried out with 
70% ethanol and UV radiation prior to use. A single T-75 flask was sufficient for seeding 
a parallel array of microfluidic cell culture models for shear stress experiments. 
Antibodies used in this study were: Primary rabbit anti-ZO-1 (GeneTex GTX108592), 
primary rabbit anti-MDR-1 (Santa Cruz sc-8313), primary rabbit β-actin (Abcam 
ab8227), secondary HRP-conjugated goat anti-rabbit (Abcam ab6721), and secondary 
Alexa Fluor 488 goat anti-rabbit (Molecular Probes A-11008). 
 
4.5 Testing Methodology 
First, the fabricated platform was evaluated on its capability of producing a wide 
range of WSS by (1) predictions based on analytical calculation and simulations and (2) 
direct flow velocity measurement from the integrated micro-flow sensor array. Next, the 
validity of the platform as the high-throughput tool to correlate full-spectrum WSS effects 





orientation angle), (4) trans-monolayer permeability, (5) TEER, and (6) protein 
expression of tight junctions and efflux transporters of the bEnd.3 cell line. 
 
4.5.1 Prediction of the Wall Shear Stress by Simulation 
In order to predict the resultant WSS levels that cells experience at the channel 
wall, (1) fine-mesh 3D COMSOL simulations were performed to obtain velocity profiles 
at different heights from the wall; (2) shear rate dU/dz at the wall was calculated by 
COMSOL based on the velocity gradient right above the wall; (3) shear rate was 
multiplied with the proportionality constant μ, or viscosity, as in the following equation 





 COMSOL simulation utilized the laminar flow module that derives velocity fields 
from the Navier-Stokes Equations. Assumptions used in the model were Newtonian fluid 
(µ=1.2mPa·s for media with serum), the no-slip condition, with equal pressure at all 
outlets. Note that the COMSOL simulations and analytical calculations also assumed that 
all flow in each of the described devices at all relevant flow-rates is completely laminar, 
with a Reynolds number several orders of magnitude lower than the turbulent threshold 
(2300), which is a reasonable assumption in microfluidics [59]. It was assumed that the 
effects of flow-induced deformation of the channel walls [60] was negligible at all 
relevant flow-rates for the study, and that the channel walls remained rigid for the purpose 






Figure 4.5 Shear stress calculation methods. All channels are 200 μm high. (A) 
WSS was simulated by COMSOL based on the vertical velocity gradient dU/dz 
multiplied by the dynamic viscosity µ. (B) Uniform velocity (70 μm height) measured by 
the micro-flow sensor was used to calculate the average shear stress   𝜏𝜏𝐴𝐴 based on the 
standard equation for shear stress in a rectangular microchannel based on the average 
velocity UA. The ratio between UA and UFS is 1.36, so this multiplication factor was used 
to derive the average wall shear stress equation for micro-flow sensor measurements. 
 
 
WSS calculation by micro-flow sensor measurements 
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Average velociity UA (z=42 µm) 





WSS is calculated by the Velocity gradient 
right next to the wall, simulated by COMSOL 





4.5.2 Shear Stress Measurement with Integrated Micro-Flow Sensors 
In parallel to COMSOL simulation, the average WSS (𝜏𝜏𝐴𝐴) at the wall was 
calculated from the velocity measurement by the fabricated micro-flow sensor (UFS) in 
each channel (Figure 4.5B). Since the fabricated microsensor was located at 70μm above 
the wall, the measurement does not directly represent the average velocity (located at 
42µm height for our device), necessitating an adjustment process in order to utilize the 
well-established relationship between the average velocity (UA) and 𝜏𝜏𝐴𝐴 in a rectangular 
channel [58]. For this adjustment, the ratio between UFS and UA, as obtained from the 
Poiseuille flow velocity profile in the vertical direction of the channel, was found to be 
~1.36, and was applied as a multiplication constant to the denominator of the standard 
equation for average WSS in a rectangular channel [58], allowing calculation of 𝜏𝜏𝐴𝐴 from 
UFS: 
 
𝜏𝜏𝐴𝐴 = 6𝜇𝜇𝑑𝑑𝐹𝐹𝐹𝐹1.36ℎ  (4.2) 
where h is channel height and μ is the dynamic viscosity. 
 To prepare for the induction of WSS into the parallel channels, fluidic 
interconnection was established by sealing marprene or silicone tubing (0.25, 0.38, 0.76, 
1.0, 1.59mm) to the inlet ports (DC734 adhesive) with 22 or 18 gauge needles and 200µl 
pipet tips. Through the ports, fluid was manipulated with a 16-cartridge peristaltic pump 
(Watson-Marlow 205S). Then, measurement utilizing the fabricated micro-flow sensor 
was performed, while certain flow rates were supplied through the platform. The 
terminals of the micro-flow sensors were connected to a Wheatstone Bridge circuit to 





DI water from a steady-flow syringe pump (KDS210) were injected in reverse through 
the outlets to generate calibration curves for each sensor. Electrical measurements were 
made with a power supply (GW Instek PSP603) and an NI DAQ. After 10s continuous 
flow, thus when flow is stable, 5V was applied and output voltage was recorded (10s, 
1kHz) through the DAQ. Following brief cooldown, the process was repeated at least 
three times. To measure the velocity distributions under forward flow, known flow rates 
were injected through the inlet, and the measured voltage outputs in each channel were 
fitted to their calibration curves to calculate uniform velocity.  
 For further comparison, volumetric flow measurements (at least 3 replicates) at 
the outlet of each chip were fit to the standard equation for average WSS:  
 
𝜏𝜏𝐴𝐴 = 6𝑄𝑄𝜇𝜇ℎ2𝑤𝑤 (4.3) 
 
4.5.3 Application of Shear Stress to Cultured Endothelial Cells 
To analyse physiological effects of WSS on confluent cultures, the platforms were 
prepared by sealing marprene or silicone tubing to inlet ports in connection to a 16-
cartridge peristaltic pump. Permeability/TEER measurement required two dedicated 
cartridges, and imaging & western blot measurement required one dedicated cartridge. 
Depending on tubing volume, 8-well strips (300 µL) with poly-tetrafluoroethylene plugs 
or centrifuge tubes lined with parafilm were used as media reservoirs. The entire 
experimental setup (pump, platforms, and reservoirs) was placed in a CO2 incubator. 
Though flow-rates differed among the four parallel channels, they were appropriate for 





fabricated platform, the platform was sterilized first with 70% ethanol and coated 
overnight with fibronectin and collagen IV (100µg/mL each) to facilitate cell adhesion. 
After sterilization, b.End3 cells were seeded in the devices at a density of 6e4/cm2 and 
allowed to adhere in a static condition (no flows) for two hours. Then the platforms were 
flushed with sterile DMEM/F12 media and perfused at very low flows (uncharacterized 
minimum pump setting) for 3 days to allow cell confluence and optimal cell anchorage. 
Media reservoirs were changed daily. Experimental WSS was applied for twenty-four 
hours prior to quantitative assays to characterize the WSS effects on bEnd.3 physiology. 
 
4.5.4 Morphometric Analysis 
In order to evaluate the shear stress effects on cell morphology, VECs were 
imaged on-chip and both shape and orientation angle of the cells were analyzed with 
CellProfiler software, while various WSS was applied to each channel. For cell imaging 
preparation, monolayers of b.End3 cells were fixed with 4% paraformaldehyde (Avantor) 
for twenty minutes at room temperature. Cell membranes were permeabilized with 0.1% 
Triton X-100 in PBS for twenty minutes. Cells were then blocked for one hour under 
gentle rotation with 5% bovine serum albumin in permeabilization buffer, and cells were 
incubated overnight at 4°C with anti-ZO-1 primary antibody. Cells were then incubated 
with Alexa-fluor 488-conjugated secondary antibody for one hour under gentle rotation. 
To visualize the cells, they were imaged with a fluorescent Nikon microscope. To 
quantitatively assess changes in cell morphology under various WSS, images were 
processed with CellProfiler to measure cell dimensions and positions (Figure 4.6A), 





Figure 4.6 Testing methodology. (A) Morphometry calculations. To quantify ZO-
1-tagged images taken at different WSS, dimensions, and orientations were analyzed with 
CellProfiler software, providing orientation angle away from flow direction, and shape 
index, defining properties of each cell. (B) Permeability assays. Fluorescent tracers of 
concentration CT were sequentially flowed in reverse through each channel outlet (with 
the other three outlets plugged) and flux was calculated by measuring tracer concentration 
in the bottom channel perfusate, and was normalized to channel junction area and top 
concentration to give permeability coefficients. (C) TEER assays. To measure monolayer 
integrity, TEER was measured by connecting electrode terminals to an EVOM epithelial 
voltohmeter, and cell resistance was found by subtracting readings by blank membrane 
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where A=area and P=perimeter.  An object with SI of 1 is a circle, and SI of 0 is a straight 
line. To quantify cell alignment, the orientation angle (OA) is defined as the angle (0-
90°) between the cell’s major axis and direction of flow. Negative orientation angles were 
inverted to their positive values. 
 
4.5.5 Permeability Assay 
In order to evaluate the shear stress effects on the cross-membrane transfer of 
molecules, the permeability of two commonly used fluorescent tracers, fluorescein 
isothiocyanate (FITC)-dextran (4kD size) and propidium iodide, was monitored in each 
channel in reference to the corresponding WSS values. Fluorescent tracer concentrations 
were measured with a BioRad Synergy plate reader for FITC-Dextran 4k (490/525nm 
excitation/emission) and propidium iodide (536/617nm), and fitted to known standards 
to calculate the concentration values. Then, the concentration values were utilized to 
calculate the corresponding permeability (Figure 4.6B). The tracer flux J through the cell 





where ΔCB is bottom perfusate concentration change, Δt is assay time, and VS is bottom 
perfusate sample volume. Permeability coefficients were calculated [61,62] for each 










where P is the permeability coefficient, A is culture area, and CT is the concentration 
being flowed through the top channel. To normalize values for blank membrane flux, 
endothelial coefficients Pe were calculated by subtracting the inverse of the measured P 
value by the inverse of coefficient Pb through a blank membrane (no cells), as in the 










4.5.6 TEER Assay 
TEER values were measured under various WSS levels to evaluate the changes 
in confluence and integrity of tight junctions. For measurement of TEER (Figure 4.6C), 
voltage and current electrode pads were connected through 30-gauge wires with 
conductive silver epoxy via an electrode adaptor (WPI) to an EVOM2 epithelial 
voltohmeter (WPI). The EVOM2 passes a constant 10µA AC current at 12.5Hz while 
measuring resistance changes. To calculate TEER, initial D0 Background resistances 
Rblank  were  subtracted  from  measured  resistance following twenty-four hour WSS R, 
and normalized for the cell culture area for that particular channel,  giving TEER values 
in Ωcm2 from:  








4.5.7 Western Blot 
Protein expression assays were performed to affirm the causes of physiological 
responses under various shear stress levels. Particularly, two proteins were monitored, 
tight junction component ZO-1 and membrane efflux transporter p-glycoprotein (P-gp), 
at multiple WSS because these proteins correlate with monolayer tightness and membrane 
transport activity. Cells were scraped from the channel substrate surface, or 6-well static 
controls, with a cell scraper and lysed. Following 10s sonication, total protein was 
centrifuged (12000RPM, 15m) and separated from pellet. Protein was quantified with 
BCA total protein assay, and 25µg protein was loaded in 4-12% Bis-Tris gels (Novex) 
and run at 200V for ~one hour, or until sufficiently separated. Following the one hour 
transfer to nitrocellulose membrane at 30V, membranes were blocked with 5% skim milk 
(one hour) in TBS-Tween-20. Rabbit primary antibodies for ZO-1, MDR-1 (P-gp), and 
β-actin as a loading control, were incubated overnight at 4°C. Goat anti-rabbit horseradish 
peroxidase secondary antibody was incubated for one hour, and chemiGlow 
(AlphaInnotech) was applied to the membrane, and imaged for band analysis with a 
FluorChem FC2 imaging system. 
 
4.6 Results and Discussion 
4.6.1 Shear Stress Simulation and Measurement 
COMSOL simulation results indicated that the horizontal profile of velocity and 
WSS within a channel is largely uniform except the high-drag regions near the side-walls 
within a distance of ~200 µm (Figure 4.7A). This uniformity helps optimize the 





Figure 4.7 WSS characterization results. (A) Horizontal WSS profile in the 
channel is largely uniform, between the high-drag regions (~200 µm) by either sidewall 
of the channel. (B) WSS distributions were found by COMSOL simulation to be 15, 4.6, 
and 2.3 times the minimum value for the parallel array, based on the vertical velocity 
gradient dU/dz adjacent to the wall in each channel. (C) Shear stress distributions between 
the four channels at 300 µL/min were compared between simulation results, micro-flow 
sensor measurements, and volumetric measurements of channel out-flows following 
timed perfusion. Values for the middle two channels were sufficiently equivalent, but 
there were discrepancies with the fastest and slowest channels for the flow-sensor results. 
Standard deviation error bars displayed, all test replicates were n>3. 
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to achieve as uniform an environment for all cells in a particular population. Due to the 
high-drag region, which is independent of channel width and only related to channel 
height, the proportion of cells experiencing lower shear stress is smaller for the wider 
channels, so the wider channels have a more homogenous profile, indicating the need for 
a high aspect ratio to optimize accuracy of WSS measurements. Though the high-drag 
regions in the smallest channel make up a slightly larger surface area than the uniform 
region (~330), its lower aspect ratio was necessary to achieve high WSS variance between 
channels.  
COMSOL simulation results also showed that uniform WSS distribution among 
four channels were repeatedly achieved with the span ratio of ~15x relative magnitude 
between the fastest and slowest channels regardless of input flow-rate (Figure 4.7B). 
Thus, the simulation results indicated that the full in vivo shear stress spectrum of 1-
60dyn/cm2 is achievable in as few as two parallel chips with two different input flow- 
rates of at least ~4x difference, allowing very rapid application and testing of the full 
physiological spectrum. 
Figure 4.7C shows the COMSOL simulation results (eq. 4.1) in comparison to the 
micro-flow sensor measurements (eq. 4.2) and estimation from the volumetric 
measurements (eq. 4.3) at an example input flow-rate of 300 µL/min. The comparison 
revealed that all three values matched within 10% error for the two center channels, 
indicating the validity of both prediction and measurement methods. The WSS values 
from the micro-flow sensors showed that the discrepancy becomes larger for the smallest 






4.6.2 Morphometric Analysis 
Image analysis data from optical measurements showed that the bEnd.3 cells did 
not exhibit any notable change in shape index, a measure of cell elongation, with increases 
in WSS (Figure 4.8A). It is known that the tested cell line in this study (bEnd.3) holds a 
characteristic highly-elongated morphology under static conditions [57], and we 
hypothesize that this trait makes the cell line less susceptible to changes in SI than other 
cell types with a rounder, more “cobble-stone” morphology under static conditions. For 
example, human aortic endothelial cells with a static SI of 0.7 have exhibited a decrease 
to 0.4 at 12 dyn/cm2 WSS [64], and bovine aortic endothelial cells with a static SI of 0.76 
have also shown a decrease to 0.31 at 20 dyn/cm2 WSS [65], while the utilized bEnd.3 
cell line has initially low SI of 0.13 or 0.1 (mean) or 0.1 (median) at static condition.  
Optical measurement data also showed that the cell lines adjusted their orientation 
with the flow direction under increasing WSS (Figure 4.8B). The mean orientation angles 
respectively decreased from 45.3° to 18.1° under the WSS range from 0 (static) to the 
highest tested at 86 dyn/cm2, while the overall trend of the mean values formed a linear 
correlation (R2 of 0.61), suggesting an increase in cell alignment with increasing WSS. 
Residual analysis of the linear regression of the orientation angle data (R2 of 0.05) 
indicated a right (positive) skew as indicated by the distribution of the residuals (Figure 
4.8C) and the normal probability plot (Figure 4.8D). In congruence, the median values 
were consistently higher than the mean values, resulting in discrete mean and median 
values in Figure 4.8. Median values also showed a linear decrease along with WSS, 






 Figure 4.8 Morphometry results. Each data-point represents measurements from 
an individual cell. Also displayed are mean and median values. (A) bEnd.3 cell shape 
index measurements with increased WSS. No trend was evident. (B) Linear regression 
analysis of orientation angle data suggested increased alignment, with an R2 of 0.051. 
Orientation angle showed a slight alignment along with WSS. The higher mean values 
than median values are expected, given the right (positive) skew indicated by the (C) 
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Experimental measurement results demonstrated that the permeability of 
chemical compounds decreased with increasing WSS. Figure 4.9 shows the resultant 
permeability coefficients of fluorescent tracers FITC-Dextran 4kD (Figure 4.9A) and 
propidium iodide (Figure 4.9B). The permeabilities of FITC-dextran and propidium 
iodide decreased from averages of 7.4e-6cm/s and 2.3e-5cm/s to 4.0e-6cm/s and 1.9e-5cm/s, 
respectively, with increasing WSS from 0.35 to 86 dyn/cm2. The decreasing rates for the 
permeability of the fluorescent tracers were 4.06e-8cm/s and 6.04e-8cm/s per dyn/cm2 for 
FITC-Dextran and PI, respectively. Minimum and maximum average values ranged from 
7.4e-6cm/s and 2.3e-5cm/s (0.35dyn/cm2) to 4.0e-6cm/s and 1.9e-5cm/s (86dyn/cm2) for 
FITC-Dextran 4kD and PI, respectively. A reduction in standard deviation was observed 
at WSS above 20 dyn/cm2. Though FITC-Dextran’s mean value increased slightly from 
64 to 86 dyn/cm2, the mean values fall within a standard error of each other. For all 
conditions, the tests were repeated at least 8 times (n>8). 
 Permeability was consistently higher for propidium iodide than for FITC-Dextran. 
This agrees with the expectation based on the lower molecular weight (668D) than FITC-
Dextran (~4kD), making diffusion more rapid. Note that for FITC-Dextran at higher WSS  
(near 86dyn/cm2) the increased mean permeability may indicate a slight loss of cell 
adhesion, but the increase is not significant, and was not observed in the propidium iodide 
permeability data, nor was a decrease in TEER observed. Potential issues with cell 
adhesion are cell line-specific, so testing of other cell types with reduced anchorage 
strength may potentially indicate losses in anchorage with the presence of “pinholes”, or 





Figure 4.9 Permeability of FITC-conjugated Dextran 4kD (A) and propidium 
iodide (B) at WSS magnitudes ranging from 0.35-84dyn/cm2 indicated a decrease in 
permeability with increasing WSS, at -4.06e-8 and -6.04e-8 unit permeability/unit WSS, 
respectively. Standard deviation was notably reduced at WSS higher than ~20 dyn/cm2. 
All sample replicates n>8. 
 
line was selected for the testing due to their characteristic high surface adherence. 
 
4.6.4 TEER 
TEER was measured with the independent electrode sets to evaluate monolayer 
integrity under varying flow conditions. In correlation with the permeability results in 
Figure 4.10, the measurement data showed that there was an increase in TEER with 
increasing WSS at a rate of 0.8Ωcm2 per dyn/cm2, ranging from 183Ωcm2 at near-static 
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 Figure 4.10 TEER measured following high shear stress was increased at about 
0.8 unit resistance/unit WSS. These data indicate increased barrier tightness with higher 
WSS, in correlation with permeability results. All replicate n>3. 
 
results, apparent anchorage losses resulting in reduced TEER was not observed at high 
WSS. 
It is noteworthy to mention that a consensus exists for BBB models that TEER 
levels must exceed 150Ωcm2 for reasonably representative permeability data to be 
obtained [66] in comparison to typical in vivo TEER levels (>1000Ωcm2). The measured 
TEER values in this paper exceeded 150Ωcm2 at all tested values of WSS. This also 
supports the use of the bEnd.3 cell line under the described culture conditions for use in 



















4.6.4 Western Blot Analysis 
The protein expression analysis data provided by western blot analysis (Figure 
4.11) showed significant increases in expression of both tight junction component ZO-1 
and efflux transporter P-gp under three distinct WSS, relative to static control derived 
from 6-well plates. The protein expression relatively increased ~5x for ZO-1 and ~6x 
for P-gp at 58 dyn/cm2 compared to the static condition (0 dyn/cm2). Notably, a larger 
relative increase in ZO-1 was observed at 14 dyn/cm2 (~5x), while P-gp expression 
increased significantly (~4x) at 4.7dyn/cm2.  
 Both proteins are known to influence trans-monolayer properties, such as 
permeability and TEER; thus the increase in the measured value in protein expression 
under increasing WSS matches well to the results obtained in aforementioned methods: 
reduction in permeability and increase in TEER with increases in WSS conditions. 
 
Figure 4.11 Densitometric relative band analysis for western blots from cell 
lysates of brain endothelial cells grown to confluence and exposed to twenty-four hours 
of WSS were compared with static controls grown in 6-wells. Results are weighted to β-
actin as a gel loading control. Static control was derived from 6-wells plates. These data 
indicate significant increases in tight junction and efflux transporter expression under 
WSS at up to an average of ~5x and ~6x for ZO-1 and P-gp, respectively, at 58 dyn/cm2 
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This paper reported the design, fabrication, and testing results of the microfluidic 
platform that enables application of the WSS range (1-60dyn/cm2) of the full 
physiologically relevant spectrum on vascular endothelial cells (VECs), while allowing 
multiple physiological, biochemical, and trans-membrane assays in a high throughput 
manner on a chip. To allow rapid full-spectrum characterization of WSS effects, we 
developed the four channel microfluidic platform that simultaneously produces shear 
stresses spanning ~15x in magnitude. Flow distributions were predicted with COMSOL 
simulation and verified by the direct measurement with a micro-flow sensor array and 
volume measurement. Multiple assays were performed, including cell morphometry, 
protein expression, permeability and TEER, on the brain microvascular endothelial cell 
line bEnd.3.  
 Morphometric image analysis showed increased alignment with flow direction 
with increases in WSS. Permeability measurement exhibited decreasing permeability 
with increasing WSS at rates of 4.06e-8 and 6.04e-8cm/s per dyn/cm2 for FITC-conjugated 
Dextran and propidium iodide, respectively. TEER measurement data showed an increase 
with increasing WSS by a rate of 0.8 Ωcm2 per dyn/cm2. Finally, the western blot results 
demonstrated notable increase in expression of a tight junction component ZO-1 and an 
efflux transporter P-gp by ~500% and 600%, respectively, compared to static controls. 
These results indicate that the bEnd.3 cell line responds to WSS in vitro in a magnitude-
dependent manner, providing insights for optimal flow conditions for dynamic VEC 
culture models.  





is a valid protocol for rapidly assaying physiological responses to the full spectrum of 
WSS, as well as elucidating limitations of practical flow conditions, for a particular 
combination of VEC cell line or primary cell type and culture conditions.  
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PERMEABILITY ANALYSIS OF NEUROACTIVE DRUGS  
THROUGH A DYNAMIC MICROFLUIDIC IN VITRO  
BLOOD-BRAIN BARRIER MODEL3 
 
5.1 Abstract 
This paper presents the permeability analysis of neuroactive drugs and correlation 
with in vivo brain/plasma ratios in a dynamic microfluidic blood-brain barrier (BBB) 
model. Permeability of seven neuroactive drugs (Ethosuximide, Gabapentin, Sertraline, 
Sunitinib, Traxoprodil, Varenicline, PF-304014) and trans-endothelial electrical 
resistance (TEER) were quantified in both dynamic (microfluidic) and static (transwell) 
BBB models, either with brain endothelial cells (bEnd.3) in monoculture, or in co-culture 
with glial cells (C6). Dynamic cultures were exposed to 15dyn/cm2 shear stress to mimic 
the in vivo environment. Dynamic models resulted in significantly higher average TEER 
(respective 5.9-fold and 8.9-fold increase for co-culture and monoculture models) and 
lower drug permeabilities (average respective decrease of 0.050 and 0.052 log(cm/s) for 
co-culture and monoculture) than static models; and co-culture models demonstrated 
higher average TEER (respective 90% and 25% increase for static and dynamic models) 
and lower drug permeability (average respective decrease of 0.063 and 0.061 log(cm/s) 
3 Reproduced by permission of Springer Publishing. Annals of Biomedical Engineering, 2014. Ahead of 
print. DOI 10.1007/s10439-014-1086-5 
 
                                                          
118 
 
for static and dynamic models) than monoculture models. Correlation of the resultant 
logPe values (ranging from -4.06 to -3.63 log(cm/s)) with in vivo brain/plasma ratios 
(ranging from 0.42 to 26.8) showed highly linear correlation (R2>0.85) for all model 
conditions, indicating the feasibility of the dynamic microfluidic BBB model for 
prediction of BBB clearance of pharmaceuticals. 
 
5.2 Introduction 
Despite increasing demands for new treatments of disorders of the central nervous 
system (CNS) such as Alzheimer’s Disease (AD) [1], CNS drug research progress has 
been significantly hindered by the prohibitive barrier from capillaries to brain tissue, the 
blood-brain barrier (BBB). Recent studies reported that AD was diagnosed in 1/3rd of 
senior deaths in the US [2], while a new case of AD is developed every 67 seconds [3]. 
However, the clinical success rates for new CNS compounds (7%) remain lower than 
other healthcare areas such as cardiovascular disease (20%) [4], while the average cost to 
develop a drug exceeded $1 billion [5]. Such low success rates have been attributed 
partially to limited prediction capability in preclinical models to assess the passage of 
drugs across the BBB [6]. The BBB, mainly comprised of the capillary’s brain endothelial 
cells, is the key barrier restricting perfusion of nearly 100% of large (>500 Da) molecules 
and 98% of small molecules [7], complicating determination of effective dose 
concentrations of drugs targeting the CNS. 
To potentially accelerate the development of new CNS-targeting pharmaceuticals, 
the high-throughput evaluation of trans-BBB properties can be achieved by developing 





vitro. The BBB preclinical models allow the discovery of rejected compounds earlier and 
enable the reduction of attrition rates in clinical trials [9]. They are capable of predicting 
whether a compound’s interaction with the BBB will compromise its functionality or 
whether it reaches the CNS in significant amounts to have a pharmacodynamic effect 
[10]. In vivo models provide similarly complex environments to human physiological 
conditions; however, they are subject to high cost, time, and ethical constraints.  In vitro 
models, within the scope of cellular physiology, resolve such issues and enable feasible 
isolation and observation of individual physiological mechanisms in repeatable and 
controllable manners, resultantly emerging as a promising alternative or augmenting 
model for early drug screening (Figure 5.1A).  
In vitro BBB models recently incorporated dynamic flows, replicating more 
realistic in vivo conditions for higher prediction capability. The flow-based dynamic in 
vitro BBB models have exploited the mechanotransductive response of endothelial cells 
to wall shear stress (WSS) and its effect on BBB functions [11-14]. For example, the 
authors’ previous dynamic models reported higher trans-endothelial electrical resistance 
(TEER) and lower permeability in comparison to traditional transwell-based in vitro 
models, better representing the cerebromicrovascular environment [15,16] found in vivo.  
Despite these advantages, dynamic in vitro models have not been widely accepted 
for BBB permeability screening in the pharmaceutical industry yet. Acceptance of in vitro 
models first requires a standard for translation of model results to the in vivo condition 
[17], in terms of its predictive ability of permeability to new compounds. Currently, none 
of the existing dynamic in vitro BBB models utilizing microfluidics [15,18-20] or hollow 























Figure 5.1 Microfluidic blood-brain barrier models. (A) The preclinical drug 
screening process would benefit from more innovative in vitro models. Though in vitro 
models are advantageous due to their low cost, time and ethical constraints, high 
experimental control over isolation of individual mechanisms, and allow a more 
repeatable and high-throughput approach, they lack the complexity of the in vivo 
environment. Microfluidic in vitro models allow higher model complexity by introducing 
a dynamic environment, while maintaining experimental control. (B) The illustration of 
the previously developed dynamic μBBB system that recreates the micro-cerebrovascular 
environment with dynamic flows and co-culture of endothelial and glial cells. Also 
included in the system is two sets of resistance-measuring AgCl electrodes. Graphic 
modified from previously published graphic [15]. 
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µBBB – multi-layered microfluidic device




Cost, time, ethical constraints
Low experimental control
Microfluidics increase in vitro model complexity & 














translational standard for permeability. The successful assessment of permeability to 
multiple CNS drugs would establish quantitative correlation with in vivo permeability, 
and demonstrate the high-throughput potential for such a dynamic model. 
We previously developed a dynamic in vitro microfluidic BBB model (μBBB, 
Figure 5.1B), and characterized the effects of chemical/pH modulation [15] and WSS 
[16] on BBB functions, such as cell morphology, fluorescent tracer permeability, TEER 
measurement by integrated electrodes, and BBB protein expression [16]. To establish 
quantitative correlation with in vivo permeability, this paper reports the permeability 
measurement of seven CNS drugs (Ethosuximide, Gabapentin, Sertraline Hydrochloride, 
Sunitinib Malate, Traxoprodil Mesylate, Varenicline Tartrate, PF-3084014) across the 
dynamic μBBB model as well as static in vitro transwell platforms prepared with both 
mono- and co-cultured BBB layers (endothelial and glial cells). Due to the abundance of 
evidence that drugs of small molecular weights (<500Da) better cross the BBB, the 
selected drugs were limited to similarly small molecular weight drugs. Then, to ensure 
inclusion of a diverse sample set, the selection preferences were given to drugs that cover 
a wide range of hydrophilicity (between -1.27 and 5.15 logPo/w), which generally dictates 
the compound’s ability to cross the plasma membrane, and have a wide range of relevant 
clinical applications including treatments for depression, epilepsy, pain, nicotine 
addiction, and tumors. Additionally, concentration-dependent cytotoxicity on brain 
endothelial cells for each drug was analyzed. For quality control of prepared cultures, 
TEER was monitored before and after each permeability test to remove outliers and 
define cell contiguity. Finally, permeability coefficients were correlated to brain/plasma 





5.3 Structure and Fabrication of the Microfluidic BBB Model 
The previously developed dynamic in vitro microfluidic BBB model has been 
utilized due to proven validation on TEER and permeability properties [15]. The 
microfluidic structure of the μBBB system (Figure 5.2A) comprised multiple layers of 
polydimethylsiloxane (PDMS) and glass substrates to form two crossing channels (4mm). 
At the junction of the crossing channels in different layers, a free-standing porous 
polycarbonate (PC) membrane [22] was embedded allowing the diffusion path from the 
top to the bottom fluidic channels. The PC membrane also provided the co-culture surface 
for both endothelial and glial cells, enabling the permeability testing through the co-
cultured BBB cell layers. On both sides of the co-culture membrane, two sets of thin-film 
electrodes were microfabricated by depositing and patterning AgCl layers on a glass 
substrate. The distance from the membrane to each electrode, equivalent to the channel 
height, was only 200μm, allowing high-accuracy TEER measurement. Each channel layer 
was connected to separate pairs of fluidic inlets and outlets for individual permeability 
analysis. 
Fabrication of the BBB model was similar to the processes described previously 
[15,16], with some modifications. First, top and bottom glass substrates were sputtered 
with layers of Cr/Au/Ag (20/80/800nm) that were patterned utilizing a lift-off process,  
forming TEER electrodes. Then the Ag surface was chlorinated chemically by dipping 
the substrate into 30mM FeCl3 for 50s to form an oxidized surface of AgCl, which is non- 
toxic with high long-term stability [23]. Second, following 30s O2 plasma oxidation at 
125W glass substrates were pressed into uncured PDMS prepolymer (10:1 





Figure 5.2: Microfluidic blood-brain barrier chip for permeability assays. (A) 
Multilayered channel structure made from patterned PDMS substrate with embedded 
glass electrode layers. Luminal (top, yellow) and abluminal (bottom, blue) channels are 
both 4mm wide and are seeded with bend.3 endothelial cells and C6 astrocytes, 
respectively, on either side of the free-standing PC membrane. Electrodes allow non-
invasive TEER measurement. (B) To test permeability through the μBBB system, the 
drug is run of constant concentration CL is run through the luminal channel for time Δt, 
and permeability is computed from the measured abluminal concentration ΔCA in sample 






































The replica mold was constructed on a Si substrate by lithographically patterning SU-8 
2075 into defining top and bottom microchannel structures. For effective bonding, top 
and bottom PDMS channel layers (with embedded glass layers) and PC membrane were 
plasma oxidized for thirty seconds, and the PC membrane was treated for thirty minutes 
with 5% 3-aminopropyltriethoxysilane (APTES) on a hotplate set to 80°C [24]. Third, all 
three substrates were pressed together at room temperature, sandwiching the PC 
membrane in an irreversible bond. The APTES-based bonding method minimized 
occurrences of leaks compared with the PDMS pre-polymer “mortar” method [22]. 
 
5.4 Materials and Cell Culture 
5.4.1 CNS-Targeting Compounds 
Seven brain-targeting commercially-available drugs were utilized for 
permeability screening of the in vitro BBB models. The seven drugs were provided by 
the Compound Transfer Program (CTP) by Pfizer Inc., including Varenicline (PF-
3430574), Gabapentin (PF-345043), Traxoprodil (PF-1486212), Sertraline (PF-579897), 
Ethosuximide (PF-344988), Sunitinib (PF-262192), and an unnamed compound (PF-
3084014). The compounds have been proven to cross the in vivo BBB to some extent, 
and represent a wide range of applications, including treatment of pain, depression, 
seizures, nicotine addiction, and tumor suppression (Table 5.1). The compounds held 
small and comparable molecular weights between 141.17 and 489.65 Da, within the 
typically known size ranges (<500Da) for efficient diffusion through BBB, and ranged 
widely in hydrophobicity from -1.27 to 5.15 logPo/w. The compounds were provided in 





Table 5.1: Compounds tested in this study. logP values are for the octanol/water 
partition coefficient Po/w. B/P is the measured in vivo brain/plasma ratios derived from 
the cited sources [25-30]. 
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or methanol below the maximum solubility. The reconstituted solutions were kept at -
20°C away from direct light to prepare stock solutions. 
 
5.4.2 Cell Culture 
Two immortalized cell lines were utilized for this permeability study, which have 
been widely accepted for BBB co-culture models, including the brain endothelial cell line 
bEnd.3 [31-33], and the glial cell line C6 [34,35], each of which was respectively derived 
from a mouse and a rat and was obtained from the ATCC. Both the cell lines were 
cultivated in DMEM/F12 media (Lonza) supplemented with 10% fetal bovine serum 
(Hyclone), with 1% Penicillin/Streptomycin and Amphotericin B (EMD) for 
contamination control. Media was buffered to 7.35 in all cases, and the cells for seeding 





The cultivated cells were seeded in 6-well transwells in both the mono-culture and 
co-culture, serving as static control for comparison to dynamic experiments with the 
μBBB chips. For high adhesion cell seeding, both the transwells and the μBBB chips 
were coated overnight with poly-lysine (100 μg/mL) and Collagen IV/ Fibronectin (100 
μg/mL each), respectively, to facilitate attachment of C6 and bEnd.3 cells. C6 astrocytes 
were seeded first on the underside of the membrane in both models at a density of 6x104 
cells/cm2. After two days, bEnd.3 cells were seeded on the top surface of the membrane 
at the same density. The seeded cells reached stable confluence on day 6 for co-culture 
and day 4 for mono-culture, when permeability experiments were performed. 
 Primary brain endothelial cells were extracted from Sprague-Dawley rats for 
morphological comparisons to bEnd.3 cells [36]. Rats were euthanized with CO2, and 
forebrains were removed, diced, and digested in 1mg/mL collagenase II and 15μg/mL 
DNAse I in DMEM with 50μg/mL gentamycin for 1.5h at 37°C under 250RPM rotation. 
Following centrifugation in 20% BSA for twenty minutes at 1000g, the re-suspended 
pellet was again digested in 1mg/mL collagenase-dispase and 6.7 μg/mL DNAse I in 
DMEM for one hour at 37°C under 200RPM rotation. Following the 2nd centrifugation 
for twenty minutes at 1000g, the further digested cells were separated on a 33% Percoll 
gradient and centrifuged a 3rd time for ten minutes at 1000g. Finally, isolated brain 
endothelial cells were plated for two days in DMEM supplemented with 10% plasma-
derived serum, 1.5ng/mL bFGF, 5µg/mL insulin, 5µg/mL transferrin, 5ng/mL sodium 
selenite, 50µg/mL gentamycin, and 4µg/mL puromycin. 500nM hydrocortisone was 
added on day 1 to improve the tightness of the cell-cell junctions; and puromycin, added 





imaged on day 5. All supplements were obtained from Sigma-Aldrich. 
 
5.5 Testing Methodology 
5.5.1 Fluorescent Imaging of Endothelial Cell Morphology 
To compare morphological properties of the bEnd.3 cell line to primary brain 
endothelial cells, the presence of tight junctions were visualized through immunostaining 
of ZO-1 expression, and all cell images were obtained in the models without electrodes. 
Following rinsing with phosphate buffered saline (PBS), confluent cells were fixed with 
4% paraformaldehyde (Avantor) for 10min at room temperature. Cell membranes were 
permeabilized with 0.1% Triton X-100 in PBS for 10min and blocked with 5% goat serum 
in permeabilization buffer for one hour. Cultures were incubated with primary mouse 
anti-ZO-1 antibody (Santa Cruz) overnight at 4°C, then incubated with secondary Alexa-
fluor goat anti-mouse antibody (Invitrogen) for one hour at room temperature. Following 
counterstaining with 1μg/ml 4’,6-diamidino-2-phenylindole (DAPI, Enzo), the cells were 
imaged with a Nikon microscope. 
 
5.5.2 Dynamic Flow Experiments 
The μBBB chips were prepared for permeability experiments under fluid flow in 
a similar process to that previously described [15,16]. The fabricated µBBB chips were 
sterilized with 70% EtOH, and connected to a 205S cartridge pump (Watson-Marlow) via 
gas-permeable marprene tubing, and the entire setup, including the pump, chips, and 
media reservoirs, was placed in a humid incubator (37°C, 5% CO2). Cells were seeded as 





bEnd.3 seeding, and flow on the luminal side was increased to 2 mL/min, providing a 
level of WSS relevant to the BBB (3-20dyn/cm2) [37]. WSS (τA) applied to the endothelial 
cells was ~15dyn/cm2 according to the equation for WSS in a rectangular channel 
 
τA = 6Qµh2w (5.1) 
where Q is flow, μ is dynamic viscosity of the media (0.012 dyn·s/cm2), and h and w are 
the channel height and width, respectively. The high aspect ratio (20:1) of the channel 
ensures that most of the cells experience a uniform WSS, except the high-drag regions 
near the side-walls [16]. 
 
5.5.3 Cytotoxicity Testing 
 To evaluate cytotoxicity levels of each drug and to establish permeability assay 
concentration limit, lactate dehydrogenase (LDH) assay (Pierce) was performed on 
bEnd.3 cells following exposure to various concentrations of each drug for twenty-four 
hours. Cells that undergo apoptosis release LDH in proportion to the level of toxicity, and 
the LDH assay reaction produces red formazan that can be measured via absorbance 
readings. To accurately quantify cytotoxicity, confluent cultures of bEnd.3 cells with a 
constant cell seeding number (9000/well) were respectively exposed to 1, 10, 100, and 
1000 μM drug concentrations in DMEM/F12 media with controlled pH of 7.35 for 
twenty-four hours in a 98-well plate. Negative controls (untreated) and positive controls 
(lysis buffer) were added to each plate to establish a basepoint and maximum levels for 
LDH release, respectively. Following the LDH assay, absorbance values were recorded 






 LDH = abs(490nm) − abs(680nm) (5.2) 
yielding responses proportional to the LDH expression in the cells. Results were reported 
as “% toxicity”, as the ratio between sample LDH response and positive control LDH 
response (100%). 
 
5.5.4 Trans-Endothelial Electrical Resistance (TEER) 
To evaluate layer contiguity of the bEnd.3 cells, and to act as quality control for 
prepared BBB cultures, TEER was monitored prior to and following each permeability 
measurement. For the transwell-based static model, the transwells with seeded cells were 
moved to an EndOhm chamber (WPI) connected to an EVOM2 epithelial voltohmeter 
(WPI). For the μBBB dynamic model, the outputs of voltages and currents from the 
embedded electrodes were connected through an electrode adapter (WPI) to an EVOM2 
epithelial voltohmeter. To calculate TEER, initial background resistances of the blank 
chip/membrane Rblank were subtracted from the measured resistance. The difference value 
was multiplied with the cell culture area A (0.16cm2 or 4.67cm2 for the chips and 
transwells, respectively), resulting in the TEER values of only the endothelial cells in 
Ωcm2 from the following equation [33]. 
 TEER = (R − Rblank)A (5.3) 
 
5.5.5 Drug Permeability 
To measure the BBB permeability of each drug, aforementioned seven drugs in 





pipetted in the static models, and concentration change on the receiving side was 
measured. To minimize the presence of media serum components in downstream LC-MS 
measurements, drugs were diluted in PBS. Each drug was injected into the luminal (top) 
side of the membrane dissolved in PBS with pH of 7.4. The permeated drugs were 
collected at the abluminal side while being perfused with pure PBS. Transwell 
permeability assays were conducted for twenty minutes, and the 1.5 mL abluminal fluid 
was collected. Dynamic permeability assays for all replicates were conducted 
simultaneously at 10 µL/min, with assay times of twenty minutes, yielding 200 µL of 
sample. All the collected samples were stored at -20°C until concentration measurements. 






where CL is the luminal concentration, ΔCA is the abluminal concentration change, VA is 
the abluminal sample volume, and Δt is the assay time. Finally, endothelial permeability 
Pe was calculated by subtracting the permeability through a blank PC membrane Pb, with 









The measured endothelial permeability Pe represents the rate of drug diffusion 
through the BBB layer, and was compared to the in vivo clearance from literature. For 
this correlation with in vivo results, measured in vitro Pe values were compared to 
brain/plasma ratios (B/P or Kp). A drug’s B/P is an optimal metric for correlation with 





pharmacokinetic (PK) profiling of compounds [39], and was thus consistently available 
for the drugs used in this study [25-30]. These values were calculated from the brain and 
plasma area under the curves (AUCs) from time/concentration profiles of in vivo 
biodistribution studies [27]. For consistency, all referenced B/P values are from PK 
studies in the rat (Sprague-Dawley), with the exception of Sunitinib (mouse, strain 
unspecified) and PF-3084014 (guinea pig). 
 
5.5.6 Sample Compound Quantification (HPLC-UV/LC-MS)  
To accurately quantify the concentrations from the tested samples, their 
quantitative concentrations (molarity) were measured by performing analysis with liquid 
chromatography (LC) and mass spectrometry (MS). First, the samples were mixed with 
mobile phases of either 0.1% formic acid in H2O or 0.1% formic acid in acetonitrile 
(ACN). The samples in the mobile phases were injected into a coupled LC-MS equipment 
setup: Agilent 1290 LC system, Agilent 6550 iFunnel Q-TOF mass spectrometer. The 
LC system utilized an Agilent Eclipse reversed-phase C-18 column. The separated 
compositions of the samples were then fed into the MS system where the samples were 
ionized (positive ion mode) through electro-spray ionization for detection. All the ionized 
compounds were detected as [M+H]+ species, intact compounds plus one proton. The 
obtained mass spectra were analyzed with Agilent Mass Hunter Quantitative Analysis 
software, where the AUC were calculated and utilized for quantification. Due to the 
structural closeness to an amino acid, the quantification of Gabapentin was performed 
utilizing a high-performance liquid chromatography (HPLC) method [40]. The HPLC-





(OPA) to the amount of Gabapentin under the incident light with wavelengths of 
340nm/455nm. The protocol analyzed the samples containing Gabapentin through 
reverse phase analysis utilizing an Insertsil PH 5µm column (4.0x150mm2, GL Sciences) 
in an Agilent 1100 HPLC system. The samples were mixed with mobile phases that 
contain Buffer A (40 mM NaPhosphate, pH7.8) and Buffer B (ACN:MeOH:H2O, 
45:45:10). The samples were first mixed with fluoraldehyde OPA reagent in a ratio of 1:2 
in the auto-injector system prior to the column injection. The mobile phase consisted of 
a gradient elution from 0% buffer B/100% buffer A to 65% buffer B/35% buffer A over 
twenty minutes, and the detector was set at the absorption wavelength of 338 nm.  
  
5.6 Results and Discussion 
5.6.1 Chromatographic Analysis 
To establish defined linear ranges for chromatographic quantitation methods, 
standard solutions of each drug in known concentrations in PBS (pH buffered 7.4) were 
analyzed to provide an interpolation standard for sample quantification (Figure 5.3). The 
resultant absorbance curves defined very highly linear ranges (R2>0.99) and were utilized 
to interpolate concentrations of each sample (Figure 5.3). In cases where a sample was 
found to be above the defined linear range, samples were diluted and run again to ensure 
accurate quantification.  
We believe that the effects of serum components on downstream measurements 
were negligible. Downstream LC-MS measurements of each of these compounds in 
serum/plasma have been conducted in previous studies by several research groups 





Figure 5.3: Linear standard curves for chromatographic detection. Standards were 
used to define a linear range, and as a quantitative standard for interpolation of sample 
results. Samples which were measured to fall above the defined linear range were diluted 
and re-run to ensure accurate interpolation. All standard curves defined a linear range 
with R2 of higher than 0.99. Analysis methods for each drug were LC-MS, except for 
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presence of media serum components was diluted by using phosphate-buffered saline 
(PBS) during permeability assays. 
 
5.6.2 Morphology 
The optical images of the immortalized bend.3 cells, obtained on day 4 of 
endothelial culture, did not show any significant dissimilarities in morphology from those 
of the primary rat brain endothelial cells (Figure 5.4). Particularly, cells from both sources 
clearly showed full confluence of highly elongated cells and strong tight junction 
expression of ZO-1 (green) among all adjacent cells. The images also showed that both 
the cell groups held comparable sizes of their highly elongated shape, typically ranging 
in 10-30µm width, and 50-80µm length. Since the monolayer of endothelial cells mainly 
determines the BBB permeability, such similarities in morphology validate the use of 
bEnd.3 cells to examine the diffusion properties of the BBB, such as TEER and 
permeability. As the zonal occludins are localized exclusively at the interface between 
cell membranes and tight junctions [47], we suspect that the background in these images 
are of secondary antibody, either nonspecifically bound or in unbound globules. Despite 
this background, the distinct boundaries where tight junctions are expressed are 




The LDH measurement results (Figure 5.5) showed that all the seven drug 





Figure 5.4:  Immunostaining of the brain endothelial cell line bEnd.3 cell line used 
for the BBB models in this study (A) and extracted primary brain endothelial cells from 
the rat (B) for reference. Cells were fixed and permeabilized, and stained with antibodies 
targeting the ZO-1 and conjugated to Alexa-fluor 488 (green), and counterstained with 
DAPI nuclear stain (blue). Cell morphologies were qualitatively similar, with strong 
expression of tight junctions as indicated by ZO-1 expression, and with similar shape and 
size, suggesting correlation with the in vivo physiology. 
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Figure 5.5: Cytotoxicity of each drug tested in this study as measured by LDH 
expression following twenty-four hour exposure to different concentrations. Data are 
reported as a ratio to LDH levels expressed by cells exposed to lysis buffer (100% 
toxicity). Also included is the negative control, or the LDH expression of untreated cells, 
indicating a baseline of negligible cytotoxicity. Standard deviations displayed with error 
bars. Conditions significantly higher than negative control denoted with *. All n=4.  
 
model up to 10µM, defining the maximum range of testing in this study. Four compounds 
(Traxoprodil, Gabapentin, Ethosuximide, and Varenicline) did not induce any increased 
LDH expression over the negative control at any measured concentrations between 10µM 
and 1mM. Compound PF-3084014 induced toxic response of 39% of positive control at 
high concentrations of 1000µM or higher, while Sertraline and Sunitinib respectively 
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these corresponding maximum acceptable concentration ranges were selected for the 
permeability assays to avoid the unrelated errors such as the loss of functioning cells due 
to toxicity. Only the selected concentrations were used as CL during permeability assays. 
Note that some in vivo toxicological information was available from MSDS 
documentation for the seven drugs utilized in this study. However, these toxicological 
tests, such as LD50 (50% lethal dose) represent the potential concentrations to poison the 
individual entity of animals, thus not providing direct translation to cytotoxicity in the 
cellular environments concerned by this study. 
 
5.6.4 Trans-Endothelial Electrical Resistance 
For this study, cells were cultured in the device only until they had reached 
confluence and steady-state TEER was reached. As a result, cell cultures have been 
maintained in the device only for up to seven days, during which any observed changes 
in electrode performance or background resistance potentially caused by protein fouling 
was not observed. TEER measurement results (Figure 5.6) showed that the change in 
average TEER before and after permeability was within 5Ωcm2 for all model conditions, 
and that outliers were observed with occurrence rates of 12.5% and 37.5% in 8 cases, 
respectively, for the dynamic BBB model and the static Transwell model, with an average 
standard deviation of 19% of the total steady-state TEER values. The outliers were 
defined as when datapoints were deviated from the average by more than 2X standard 
deviations. It was hypothesized that outliers were caused by pinholes in the bEnd.3 cell 
layer or by apoptosis due to cytotoxicity by the tested drugs. The TEER measurement 





Figure 5.6: TEER level s of prepared BBB models, four days after endothelial cell 
seeding as quality control. TEER was measured before and after permeability assays, and 
outliers were selected and removed as unacceptable for permeability testing. TEER for 
co-cultures (A,C) were significantly higher than for mono-cultures (B,D), and TEER for 
the μBBB cultures (A,B) were significantly higher than static transwells (C,D). Standard 














































exclusion of outliers. 
As shown previously [15], co-culturing bEnd.3 cells with astrocytes results in 
significantly elevated TEER levels of BBB models in both static (~90% increase) and 
dynamic (~25% increase) conditions. These TEER levels indicate more fully contiguous 
cell layers and more strongly expressed tight junctions [48], though they are not indicative 
of cell transcytotic activity [49], which is the primary path for compounds that cannot 
pass through tight junctions. 
Finally, TEER levels were measured to be significantly higher for dynamic µBBB 
compared with static transwells for both co-cultured (5.9 fold increase) and mono-
cultured (8.9 fold increase) BBB models. A consensus has been reached regarding BBB 
models that a minimum TEER level of 150Ωcm2 is required for BBB models to achieve 
reasonably representative and consistent permeability characteristics [50], and this 
threshold was consistently reached for both monocultured (223 Ωcm2) and co-cultured 
(280 Ωcm2) embodiments of the dynamic µBBB model, but not for their static transwell 
counterparts (47 and 25 Ωcm2). This indicates that the dynamic model represents a 
significant improvement in terms of monolayer tightness. 
 
5.6.5 Drug Permeability 
The feasibility of the BBB model as a predictive platform for drug screening was 
tested with peremability measurement of the seven drugs (Table 5.2, Figure 5.7). 
Comparison of the logPe averages across all seven drugs appear to suggest two trends in 
permeability: (1) lower permeability in co-cultured models than in monocultured models, 





Table 5.2: Permeability results of each compound used in the study. Standard 
deviations displayed after each result. Data is presented in Figures 5.8-5.9 as logPe 
according to convention. All n=4. B/P ratios from previous studies [25-30]. 
 
the drug logPe coefficents of monocultured models were, on average, 0.063 and 0.061 
log(cm/s) lower than for co-cultured models in static and dynamic conditions, 
respectively, while the average LogPe coefficients were lower in the dynamic in vitro 
BBB models than static Transwell models by 0.050 and 0.052 log(cm/s) for co-cultured 
and monocultured models, respectively (Figure 5.8). These trends indicate that optimal 
model conditions in regards to highest barrier performance are achieved by dynamic co-
cultures. These trends are consistent with the highest TEER values obtained in dynamic 
co-culture conditions.  
For all model conditions, there was a strong correlation with in vivo B/P ratios 
with linear regression accuracy of R2>0.85. As the B/P ratio increased from 0.42 to 26.8, 
the corresponding average logPe values of each drug proportionally increased from -4.06 
to -3.63 log(cm/s) (Figure 5.9). Though multiple-drug correlation of brain clearance 
results between transwell-based in vitro models and in vivo animal models has been 
shown previously [17,51], this reports the first demonstration of in vivo correlation for 















PF-262192 0.42  87+13 97+4 104+29 104+7 
PF-345043 0.75  109+7 119+18 110+17 118+27 
PF-3084014 1        93+12 105+14 108+9 151+7 
PF-344988 1.1    128+10 133+2 144+7 146+12 
PF-1486212 2.1    131+37 153+43 162+49 175+28 
PF-3430574 3.24  163+78 173+19 195+57 199+40 
PF-579897 26.8  208+20 237+36 229+7 294+19 





Figure 5.7: Permeability coefficients of each compound used in the study. Data 
are presented in Figure 5.8-5.9 as logPe according to convention. Dynamic conditions 
significantly different than transwell controls denoted with *. All n=4. 
 
confirmed correlation results, in addition to the practical advantages of the µBBB (high-
throughput, material conservation, integrated sensing, controlled delivery), demonstrate 
that microfluidic models are a promising tool for pharmaceutical drug screening. 
No correlative trend was deterministically exhibited between permeability 
profiles or B/P and logPo/w (octanol/water coefficient) or molecular weight, implying the 
potential influence of other physicochemical properties on diffusive properties of the 



















Figure 5.8: Comparison of average static/dynamic BBB permeability coefficients 
(logPe) between static and dynamic models, where dynamic logPe corresponds to the y-
axis, and static logPe corresponds to the x-axis. In the case of both co-culture (A) and 
mono-culture (B) versions of the models, drug logPe of static BBB models with otherwise 
similar culture conditions were higher than their corresponding logPe (dotted line), with 
an average offset of 0.050 and 0.052 for co-cultured and monocultured versions of the 
model, respectively. These results indicate that dynamic models provide higher barrier 
activity and better model performance, in agreement with the higher model TEER values. 
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Figure 5.9: In vivo correlation of averaged permeability coefficients (see Table 
5.2). Data are displayed as logPe according to convention. Drug brain/plasma ratios were 
referenced from literature. In the case of both co-culture (A) and monoculture (B) 
versions of the models, permeabilities were consistently lower for dynamic μBBB than 
static transwells, indicating increased barrier function. All cases showed a highly 
correlated positive trend with brain/plasma ratio, indicating that the BBB model is 
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properties of the tested compounds as well as requirement of a larger dataset of 
compounds tested in this study has currently limited more comprehensive, multi-
descriptor quantitative structure-activity response (QSAR) analysis [52]. However, 
within the limited testing, Sertraline, which exhibited the best BBB clearance, showed 
both the highest logPo/w (octanol/water coefficient), thus the highest lipophilicity, and the 
highest logPch (alkane/water coefficient), indicating a lack of polar interactions [53], 
likely explaining its comparatively excellent brain penetration in the test group. This is 
because capacity factors (polar interactions per surface unit) have exhibited a 
significantly-decreasing correlation with BBB permeability of compounds [54]. 
 
5.7 Conclusions 
We have demonstrated the permeability analysis of neuroactive drugs and 
correlation with in vivo brain/plasma ratios in a dynamic microfluidic blood-brain barrier 
(BBB) model. Seven neuroactive drugs, including Ethosuximide, Gabapentin, Sertraline, 
Sunitinib, Traxoprodil, Varenicline, PF-3084014, were analyzed in terms of TEER and 
permeability in both dynamic (microfluidic) and static (transwell) BBB models  either 
with brain endothelial cell line bEnd.3 in monoculture, or in co-culture with glial cell line 
C6. For all seven drugs, dynamic and co-culture models respectively resulted in lower 
permeability, and significantly higher TEER, than static and monoculture models, 
providing the justification for the dynamic co-culture microfluidic BBB model utilized in 
this study. Correlation of the resultant logPe values (ranging from -4.06 to -3.63 
log(cm/s)) with in vivo brain/plasma ratios (ranging from 0.42 to 26.8) showed highly 





dynamic microfluidic BBB model for prediction of BBB clearance of pharmaceuticals. 
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6.1 Summary and Impact 
The purpose of this project was to develop and characterize an innovative chip-
based platform for blood-brain barrier (BBB) modeling with advantages over the state-
of-the-art: Compared with in vivo models, (A) lower costs, timescales, and ethical issues 
than in vivo studies; (B) Massively-parallel, controlled and repeatable environments, and 
easier elucidation of molecular mechanisms; Compared with transwell models, (C) a 
dynamic microenvironment providing shear stress stimulation to the constituent cells, 
also allowing controlled delivery of test compounds and improved permeability analysis; 
Compared with hollow fiber models, (D) much thinner culture membrane, decreasing the 
distance between co-cultured cells for compound diffusion, and (E) smaller functional 
volumes for quicker media exchange, material conservation, and scales closer to true in 
vivo dimensions, and (F) a 2D culture surface allowing complete initial seeding and 
shorter times to steady-state barrier resistance for a more rapid turn-around time, 
shortening experiments and allowing a more high-throughput approach to 
experimentation. The systems primary applications include (1) use as a platform to test 
responses of the cultured cells to chemical and physical stimuli, and (2) use as a drug 




studies in the preceding chapters fully demonstrated these applications. 
Chapter 3 demonstrated the first publication of a microfluidic BBB model (μbbb) 
[1]. However, since its publication, three other groups have published chip-based 
microfluidic BBB models, though the publications in this dissertation remain the most 
comprehensive in comparison. Indeed, the μBBB remains the only microfluidic BBB 
which has simultaneously measured trans-endothelial electrical resistance (TEER) and 
permeability within the same system, and the only system to test more than a single 
magnitude of on-chip discrete shear stress, or to test the passage of actual drugs through 
the system (Table 6.1). The first, “BBB-ON-CHIP” [2] focused on modulation of BBB 
properties (TEER) in response to tumor necrosis factor alpha (TNF-α); however, they did  
 
Table 6.1 Comparison of microfluidic BBB studies reported at the time of this 
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not measure permeability, and did not co-culture the cells with astrocytes, though they 
did run experiments within the physiologically relevant range of shear stresss 
(5.8dyn/cm2). Notably, they used nearly identical structures and methods to a previous 
paper on resistance measurement across epithelial barriers by the Takayama group [6]. 
The second, “neurovascular unit-on-a-chip” [4] focused on constructing a co-cultured 
system with the RBE4 cell line and a mixture of primary neurons and astrocytes at 4% 
and 96% population, respectively. Though they tested permeability of the fluorescent 
marker Alexafluor-dextran through the co-culture and also looked at modulation of 
permeability by TNF-α, the system cannot measure TEER, is a noncontact co-culture, 
and was not operated under specified shear stress levels. The third, “synthetic 
microvascular model (SyM-BBB)” [5] differs in concept in that it uses micropillar gaps 
in the walls between two adjacent chambers instead of a porous membrane, and measured 
permeability of fluorescent tracer fluorescein isothiocyanate (FITC) with microscopy 
rather than with a plate reader. However, the system is not feasible for TEER 
measurement, only extremely low shear stress was used, and barrier modulation was not 
demonstrated. In short, the described μBBB system remains the best characterized 
microfluidic BBB model to date. 
 
6.2 Unpublished Results 
In Chapter 3, the cell lines selected for study in the presented µBBB were 
observed for key morphological properties, confirming expression of glial fibrillary 
acidic protein (GFAP) by C8-D1A astrocytes, and localized expression of key tight 




microscopy. An additional key component that should be expressed by BBB endothelial 
cells is P-glycoprotein (P-gp) [7], because it acts in concert with tight junctions to exclude 
trans-cellular passage of compounds by efflux transport. While protein expression by 
bEnd.3 cells under static and dynamic conditions was tested by western blot in Chapter 
4, we conducted a biochemical assay to confirm significant quantifiable activity of P-gp 
in bEnd.3 cells. To quantify P-gp activity, we used the Multi-Drug Resistance (MDR) 
assay made by Cayman Chemical. The assay allows measurement of cellular uptake of 
Calcein AM (acetomethoxy), which loses its AM group when exposed to intracellular 
esterases, both emitting fluorescence and trapping the Calcein within the cell. Populations 
of bEnd.3 cells were seeded in 96-well plates at 5x104 cells/well, and were assayed for 
MDR activity on the next day. To act as a control group representing zero efflux activity, 
20 µM Cyclosporin A, a competitive inhibitor of P-gp and other MDR efflux transporters, 
was treated to one set of wells for thirty minutes to simulate cells with no efflux activity. 
Following Cyclosporin A treatment, both groups and media-only background control 
were incubated with Calcein AM staining solution for twenty minutes, when fluorescence 
was measured with a plate reader at 485nm and 535nm excitation and emission, 
respectively. Results indicated that the untreated bEnd.3 cells uptook approximately 32% 
less Calcein AM than the Cyclosporin A-treated control (Figure 6.1). Thus, in the 20 
minute biochemical assay time, efflux transporters on the bEnd.3 cell membrane reduced 
Calcein AM entry by 32%. This result confirms quantitatively significant P-gp expression 
by bEnd.3 cells used in this dissertation, supporting justification of its use in these studies. 
Two different astrocyte-type cell lines were used in Chapters 3 and 5 of this 







Figure 6.1 Relative Calcein AM uptake by bEnd.3 cells. 96-wells seeded with 
equal number of bEnd.3 cells (5x104 cells/well) were treated on day 1 with 20 µM 
Cyclosporin A for thirty minutes to inhibit efflux activity for comparison with untreated 
control. Results indicated significantly lower Calcein AM uptake by the untreated cells, 
at approximately 32% lower amounts than cells inhibited with Cylcosporin A. All n>3. 
 
characterization study; however, its proliferative properties were inferior to bEnd.3 
making evenly developed co-cultures tedious; therefore subsequently, the C6 glial cell 
line was used because it was commonly used in previous co-culture BBB models [8,9] 
and to generate astrocyte-conditioned medium [10], and because its proliferative 
properties were comparable to bEnd.3, typically reaching confluence in less than 4 days. 
To compare their morphologies, immunostaining was done to label GFAP as follows: 
Cells were fixed with 4% paraformaldehyde for 10m at room temperature. Cells were 
permabilized with 0.1% Triton X-100 in PBS for 10m and blocked with 5% bovine serum  
albumin permeabilization buffer for one hour. Cultures were incubated with primary 
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solution and left in secondary antibody for one hour, counter-stained with DAPI (blue) or 
propidium iodide (red) for 5m, and imaged with a Nikon fluorescence microscope. Rabbit 
anti-GFAP (Invitrogen) was used in conjunction with Alexa Fluor 488 goat anti-rabbitt 
secondary antibody (Invitrogen). Morphological analysis of cell lines indicated that both 
cell types showed comparable morphology and size, with process arms branching 
outward from small somata (Figure 6.2). Nucleui is counterstained with DAPI (blue) or 
propidium iodide (red). These comparable morphologies, the excellent growth properties, 
and heavy amount of previous studies with the cell line support the use of the C6 cell line 












Figure 6.2 Morphological images of both astrocyte cell lines used in this 
dissertation, stained on day 2 of culture. Both cell types were fluorescently stained with 
anti-GFAP antibody, a glial marker (green). Both cell types showed comparable 
morphology and size, with process arms branching outward from small somata. Nucleus 












With the aim of retroactively measuring size exclusion characteristics of the three 
different types of FITC-conjugated dextrans used in Chapter 3, equal concentrations (500 
μg/ml) of each size diluted in DMEM/F12 media were run through a standard FPLC 
column to test for differences in size distribution and confirm the accuracy of the supplier-
provided average molecular weights for each type of compound (4, 20, and 70 kDa 
average molecular weight). The elution profiles of each solution are displayed in Figure 
6.3. Size-exclusion measurements of each type of compound showed 5 distinct peaks at 
the same elution time; however, it was expected that distinct peak locations would be 
present for each compound of different size. It is likely that this is due to degradation of 
  
Figure 6.3 Size-exclusion elution profiles of FITC-conjugated dextrans used in 
Chapter 3 permeability assays following 3 years of storage in aqueous solution. Elution 
profiles, with five distinct peaks located at the same elution time, indicate significant 































the compounds to their commonly stable polymeric fragments, because the tested samples 
were stored as solutions in DMEM/F12 media (5⁰C) for more than 3 years following 
permeability measurements, before the size exclusion tests were conducted. Dextran’s 
stability in aqueous solutions is not well described, but is not suggested by the 
manufacturer (Sigma-Aldrich) for long-term storage. This result demonstrates the 
importance of sample characterization at approximately the same time-frame as sample 
permeability analysis. 
 
6.3 Further Commentary 
 Further commentary supporting the studies in the previous chapters will be 
discussed in this section, in addition to that discussed within the chapter discussions 
themselves. First, discussion is necessary on the highly significant difference in TEER 
observed between the chip-based studies and the transwell controls under identical cell 
culture conditions, resulting in nearly an order of magnitude difference. There is a high 
body of evidence that the mechanotrasductive response of endothelial cells to shear stress 
includes significant increases in tight junction expression [11-15], and this increase in 
tight junction expression was observed in Chapter 4, indicated by western blots of 
dynamic cultures and static controls. These evidences support the explanation that the 
presence of shear stress in the system induce significant changes in the endothelial cells, 
even at very low flows (0.02 dyn/cm2). It is also possible that part of the increase in TEER 
can be explained by the large area differences between the two systems (0.16 cm2 for the 
microchip, and 4.67 cm2 for transwells), perhaps due to higher occurrences of “pinholes” 




show a significant difference: transwell cultures of bEnd.3 cells have shown comparable 
results to our 6-well static control (4.67cm2, 20-30 Ωcm2) in both 12-well formats [16] 
(1.13cm2, 29-31 Ωcm2) and 24-well formats [17] (0.33cm2, 30-34 Ωcm2). These 
differences between areas are not significant, so it is most likely not a notable contributing 
factor to discrepancies in TEER between systems used in this dissertation. 
 The relationship between TEER and permeability was not discussed explicitly in 
the preceding chapters either. Differences between permeability results in chip-based 
cultures and static controls were not as significant as differences in TEER. However, it 
should be noted that the relationship between TEER and solute transport is not necessarily 
linear, because solute transport depends on a combination of paracellular transport (which 
is effectively described by TEER) and transcellular transport, which is independent of 
TEER [18]. It has been shown before that at TEER values higher than about 130 Ωcm2, 
solute permeability was independent of TEER status [19], so the relationship between 
TEER and permeability are not directly correlated, except at very low levels of TEER. 
 Little justification was provided in Chapter 3 for modifying pH. In ischemic 
conditions, the pH in the brain can change significantly, resulting in pH changes and 
increased permeability through those particular regions. Thus, studying the relationship 
between pH and BBB permeability is relevant to studying pathological conditions of the 
BBB. In addition, heightened pH has been suggested as a permeability enhancer for 
delivered drugs. For example, significant increases in nicotine and the marker mannitol 
have been shown in vivo and in vitro under increases in pH, particularly at pH levels 
higher than 9 [20,21]. Thus, the feasibility of testing pH effects in the microfluidic model 




Finally, more in-depth physic-chemical descriptions of the selection of drugs 
tested in Chapter 5, and the macromolecules and small fluorescent molecules tested in 
Chapter 3 and 4, are provided in Table 6.2. The seven Pfizer CNS drugs exhibited the 
highest permeability compared with the fluorescent tracers, but there is no clear 
physicochemical correlation across all drugs. Sertraline, the compound having both the 
highest logP (octanol/water coefficient) and thus the highest lipophilicity, the highest 
biologically relevant logD (distribution coefficient at pH7.4), and the lowest polar surface 
area, had the highest BBB model permeability results. Each of these physicochemical 
characteristics have been shown to contribute to BBB permeability [22,23]. Finally, the 
 
Table 6.2 Physicochemical properties and dynamic in vitro results of each of the 
compounds tested in this dissertation. Properties are referenced from the chemical 
database ChEMBL. 












Sertraline 306.2 5 3.04 1/1 12.03 2 208+20 High 
Varenicline 211.3 1.04 -1.06 3/1 37.81 2 163+78 Low 
Traxoprodil 327.4 2.4 -0.16 4/3 63.93 2 131+37 Low 
Ethosuximide 141.2 0.54 0.25 2/1 46.17 0 128+10 Low 
Gabapentin 171.2 -1.49 -1.42 3/3 63.32 0 109+7 Low 
Unnamed 489.6 5.04 2.75 4/3 70.98 2 93+12 Low 
Sunitinib 398.5 3 0.44 4/3 77.23 2 87+13 High 
Propidium 
Iodide 
414.6 3.4 -1.89 2/2 55.92 4 7.9+2.9 Low 
FITC-Dextran 
4kD 





0 3.08+0.16 Low 
FITC-Dextran 
20kD 





0 1.84+0.97 Low 
FITC-Dextran 
70kD 









FITC-Dextrans have the lowest permeability due to their significantly higher molecular 
weight and highly hydrophilic and polar physicochemical properties. 
 
6.4 Future Work 
This dissertation has demonstrated the feasibility of such a system for both 
applications: (1) measurement of barrier properties and testing of barrier modulation; (2) 
predictive assay platform for the clearance of compounds targeting the central nervous 
system. However, this dissertation represents an introductory pilot study to the novel 
concept of the microfluidic BBB model, which is intended to act as a launching point for 
several focused projects that will both benefit from and contribute to the foundations it 
has provided with the presented studies. 
 
6.4.1 µBBB Model Optimization 
The studies described in this dissertation have successfully accomplished 
considerable progress toward validating the feasibility of this type of system for use in 
the pharmaceutical industry. However, there are further characteristics of the model 
which can be optimized, in order to further hone the achieved barrier properties of the 
system and increase its practical efficacy. Further research is required to optimize the 
design of the system and further assess its benefits. 
 
6.4.1.1 Primary Cells and Cell Culture Properties 
The immortalized cell lines used in this dissertation have provided extremely 




in Chapter 2. However, primary cells are recognized as an optimal standard for BBB 
models. This is because relatively high correlations with in vivo models in terms of TEER 
and tight junction expression have been observed, though this advantage diminishes after 
only a few passages [24]. Furthermore, to achieve the ideal in vitro condition for 
translation of in vitro prediction to clinical efficacy, primary human cells rather than 
animal cells should be used. Since their origin is the brain, such endothelial cell culture 
isolations can only be obtained from surgical resections during autopsy or temporal 
lobectomy. Cerebral cortex fragments will be minced, homogenized in dextran, digested 
using collagenase/dispase, and isolated with a Percoll gradient procedure as has been 
described previously [25]. Results with the model are expected to exhibit significant 
increases in TEER, since in previous studies, TEER levels with significantly higher 
results have been achieved within the same laboratory with the same physical model and 
TEER measurement techniques in comparison with immortalized cells. However, 
limitations of adhesion are expected, and optimization of flow conditions and adhesion 
protein coatings will be required to ensure successful cell culture upon integration into 
the microfluidic device. 
In addition to endothelial cells and astrocytes, a third cell type, the perictye, is 
present in vivo and covers approximately a quarter of the abluminal endothelial surface, 
playing a role in endothelial proliferation and inflammatory processes [26], though there 
have been difficulties in isolating this cell type due to lack of specific markers, therefore 
its use in BBB models have been somewhat limited. It would be pertinent to include 





6.4.1.2 Membrane Materials 
The track-etched polycarbonate membranes used in this study were primarily used 
because they are identical to those used in transwells, providing experimental consistency 
with the static controls used, though they are one of many options for porous membrane 
materials which could be used in the model. Track-etched polyetheyle terephthalate 
(PET) are transparent, allowing light-based microscopy during cultures [27]. These track-
etched membranes are not flexible, and tend to tear under too much mechanical stress. 
Other, highly flexible materials such as polydimethylsiloxane (PDMS) could be used 
instead to allow application of stretching mechanics to cell layers [28]. Such an approach 
could, for example, be used for testing of barrier modulation under conditions of physical 
trauma to brain vascular systems. 
 
6.4.1.3 Electrode Properties 
While the thin-film Ag/AgCl electrodes fabricated for the described μBBB were 
sufficient for the short-term experiments from this dissertation, they will need to be 
characterized for long-term stability and drift for long-term cultures to increase the 
throughput potential of the system. Optimization of electrode properties will be pertinent 
for future study. Electroplated AgCl has been shown to have improved long-term 
performance over sputtered AgCl [29]. Conversely to the microfabricated AgCl thin-film 
electrodes used in these studies, many different types of electrodes have been used for 
measuring TEER of endothelial or epithelial cells, including commercial silver/silver 
chloride electrodes [6,30], or alternate materials such as platinum [2], aluminum and 




[34] coatings on electrode systems could potentially improve their stability and long-term 
performance. Finally, to remove the need for integrating glass substrates, print-and-peel 
fabrication methods have been demonstrated to deposit copper and silver electrodes 
directly onto flexible PDMS substrates with reasonable performance [35]. 
 
6.4.1.4 Direct Comparison with an Animal Model 
Though multiple-drug correlation of brain clearance results between transwell-
based in vitro models and in vivo animal models has been shown previously [37,38], 
Chapter 5 reports the first demonstration of in vivo correlation for pharmaceutical drug 
clearance in a dynamic microfluidic model of the BBB. Though strong quantitative  
correlation between in vivo brain/plasma ratios (B/P) and in vitro permeability (Pe) was 
observed, B/P is not exclusively defined by BBB permeability, as it also involves other 
factors such as protein binding and brain metabolism [39,40]. Thus, a more direct, 
calculable correlation between in vitro and in vivo permeability for accurate quantitative 
prediction using the microfluidic model would best be achieved by calculating the in vivo 
BBB permeability-surface area product (PS) for each compound.  
To measure PS with the animal model (Figure 6.4) [41], animals will need to be 
anesthetized with ketamine and xylazine, and body temperature will be maintained at 
37°C with a heating pad. The right common carotid artery, which runs directly to the 
brain, will be exposed and ligated with the occipital artery, and cannulated with tubing 
connected to a syringe pump. Next, the heart is stopped by severing the ventricles, and 
the perfusion of the test compound diluted in a bicarbonate-buffered saline solution is 












Figure 6.4 Permeability measurement of the BBB in vivo. Direct short-term 
permeability of the BBB can be measured in vivo by exposing and cannulating one of the 
carotid arteries, and perfusing a test compound prior to decapitation and measurement. 
From Nicolazzo [36]. 
 
[42], for a short duration >60s. Following the perfusion, the animal is immediately 
decapitated, and the brain tissue is excised, weighed, and digested in tissue solubilizer for 
scintillation counting. The measured brain concentration CB is related to the initial uptake 
clearance Clup [43] by the equation 
 𝐶𝐶𝐵𝐵 𝐶𝐶𝑝𝑝 = 𝐶𝐶𝐶𝐶𝑢𝑢𝑝𝑝𝑇𝑇 + 𝑉𝑉𝑎𝑎⁄  (6.1) 
where Cp is the perfused concentration, T is perfusion time, and Vv is the brain’s vascular 
volume. Finally, the permeability coefficient PS is computed from the following equation 
where F is the regional flow rate [42]:  
 𝑃𝑃𝐹𝐹 = −𝐹𝐹𝐶𝐶𝐹𝐹�1 − 𝐶𝐶𝐶𝐶𝑢𝑢𝑝𝑝 𝐹𝐹⁄ � (6.2) 
Thus, a more direct, calculable correlation between in vitro and in vivo permeability for 
more direct quantitative prediction could be achieved for characterizing correlation of 




BBB permeability between the developed microfluidic model and the physiological 
condition.  
 
6.4.1.5 Adoption of the Model by Industry 
 Adoption of such microfluidic models by the pharmaceutical industry for early-
stage in vitro drug permeability screening is supported by the currently rapid increase of 
microfluidics in industry. The global microfluidics market was valued at $1.59 billion, 
attributed largely to the growing adoption of in vitro diagnostics for point of care, and is 
projected to reach $3.57 billion by 2018, with the drug delivery devices market expected 
to undergo the fastest growth during that time [44]. Adoption of microfluidic models for 
mainstream drug research and development has not yet occurred, though AstraZeneca has 
recently announced a collaboration with Harvard’s Wyss Institute to research the 
integration of microfluidic cell culture models into their drug development process [45]. 
The primary challenge for adoption of organ-on-chips in this process is establishment of 
reliablie in vivo correlation. The effective in vivo correlation requires side-by-side studies 
between model results and in vivo results in terms of permeability, toxicity, as well as 
drug efficacy. The proof-of-concept for this in vivo correlation was demonstrated in this 
dissertation. 
In addition, commercialization of the μBBB devices will require device 
fabrication and process design to optimize the robustness of the model for use by various 
researchers, and to allow large-scale manufacturing. While many of the fabrication 
processes in this dissertation were conducted by hand, automation of device fabrication 




chips. For consistency of such large-scale experiments, automation should be integrated 
into the system in every feasible way. For example, microfluidic chips have been 
designed that are capable of performing fully automated cell culture, including cell 
seeding and treatment with growth factors [46], allowing high versatility and 
repeatability, independent of the researcher performing experimentation. Such 
automation processes are key to large-scale mainstream industry adoption. 
 
6.4.2 Screening of Novel BBB-Crossing Macromolecules 
Up to date macromolecular drug delivery carriers have not proven to reach the 
CNS in effective pharmacological concentrations, though such routes are promising for 
future clinical application because they take advantage of specific receptors bound to 
endothelial cells. There is considerable interest in testing the effectiveness of such 
macromolecules for BBB passage, and the use of the microfluidic BBB model for this 
purpose is a potential future direction for this work, especially when various forms of the 
compound are available with a wide range of physicochemical properties. Novel drug 
delivery systems can be tailored for their physicochemical properties, making them 
potentially valuable vectors for targeting the blood-brain barrier. Poly (amidoamine) 
(PAMAM) dendrimers have been extensively studied for drug delivery applications [47]. 
First, they are available in a number of sizes, dependent on generation number, resulting 
in incremental increases in size. Furthermore, generation number increases molecular 
weight, the number of branches, and thus the number of terminal amine surface groups, 
each with their own diffusion times based on size and polarity. Second, surface 
modification onto the surface amine groups with different types of chemical groups, such 




surface charge, number of lipid chains, and concentration, have been shown to lead to 
changes in permeability, functionality, and toxicity in Caco-2 epithelial cells [50,51]. It 
is reasonable to assume that such correlations of physicochemical properties of 
dendrimers with transport across epithelial and endothelial barriers such as the BBB are 
similar, nevertheless high-throughput testing of permeability of these compounds through 
the µBBB model and transwell/animal controls will be needed. 
 
6.4.3 Toward a Complete Neurovascular Unit 
 The complete neurovascular unit is considered to comprise of the BBB multi-
cellular component, the capillary and connected astrocytes, in addition to the adjacent 
neurons in the surrounding parenchyma [52], which are typically the target of CNS drugs 
(Figure 6.5A). Though neuron processes do not directly contact the capillaries as 
astrocyte processes do, there is sufficient evidence that neurons influence the BBB [53]. 
Co-culturing neurons or neural progenitor cells with endothelial cells in BBB models can 
have similar influence on barrier function as astrocyte co-culture [54,55], presumably 
through cell-cell signaling. Thus, further investigation of the interplay between neurons 
and the BBB is warranted. 
A compartmentalized microfluidic model would allow isolation of the BBB and 
cultured neurons in separate compartments to permit integration of specialized 
microsensors in each chamber, and allows diffusion of test compounds and secreted cell 
signaling factors between the chambers in a tunable manner (Figure 6.5B). Though 
chambers are separated spatially in the mm scale, the channel height is in the µm scale, 




Figure 6.5 The microfluidic neurovascular unit concept (μNVU). (A) The 
neurovascular unit comprises of the BBB and the adjacent neurons. It is possible that 
these neurons play a role in BBB function. (B-C) To model the interplay between neurons 
and the BBB, a compartmentalized microfluidic device can isolate neurons from the 
BBB, while allowing diffusion of soluble factors and enabling independent 
monitoring/manipulation. (D) Prototype µNVU has been built; not yet characterized. 































dominated by diffusion, as in brain tissue. Such a microfluidic neurovascular unit 
(µNVU, Figure 6.4C) has two applications: (1) BBB clearance and PD effect on (or 
cellular uptake by) neurons can be investigated simultaneously. (2) Secondary influence 
of neuron stimulation on BBB function can be observed. Electrical stimulation of neurons 
has been seen to induce neuronal activity in vitro [57-59] and in vivo [60-62]. Opening of 
the BBB has been observed in tissue surrounding implanted recording electrodes [63,64], 
though this has been attributed to the injury related to insertion trauma. It was recently 
shown that fifteen minutes of 50-100µA subcutaneous electrical stimulation at rat 
whisker pads induced transient BBB passage of IGF-1 in vivo, localized to the stimulated 
region, and the authors attributed this effect to the stimulated increase in neuronal activity 
[65], not electrical damage as has been previously attributed following several days of 
continuous stimulation [66]. This indicates BBB modulation through neurovascular 
coupling, and could have significant clinical implications for drug delivery. To our 
knowledge, the relationship between neuronal stimulation and BBB function has not been 
examined in vitro; therefore, a prototype was fabricated to test this relationship, though 
it has not yet been characterized or tested (Figure 6.4D). A second application of this 
design is recording changes in neuron activity in response to a perfused drug, thus 
allowing simultaneous monitoring of pharmacokinetic BBB clearance and 
pharmacodynamic neuron response. 
 
6.4.4 Integration into a Body-on-a-Chip 
 An emerging branch of microfluidics uses compartmentalization to allow 




manipulation and observation of the respective cell populations [67-69]. Shuler and 
colleagues previously developed the concept utilizing microfluidics to compartmentally 
model physiologically-based pharmacokinetic models (PBPK) [70], allowing effective 
elucidation of absorption, distribution, metabolism, excretion, and toxicity (ADMET) 
properties relating to multiple organs. These body-on-a-chip platforms, also coined 
microscale cell culture analogues (µCCAs), have been developed to model multiple 
organs, such as lung, liver, fat, or marrow into isolated chambers, while allowing 
integration of biosensors such as oxygen sensors [71,72].  Thus, these single systems 
allow modeling of realistic metabolism, distribution, and toxicities of tested compounds 
in a manner not possible with simpler models.  
Though body-on-chips have been developed to include barrier components 
representing the gastrointestinal tract to model oral adsorption in combination with 
interaction with individual organs on the same chip [67-69] or in a separate module in 
connection with peripheral organs [73], such a system is yet to be integrated with a BBB 
component to allow simultaneous monitoring of systemic interaction and BBB passage.  
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